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SUMMARY 
 
 The following research was undertaken to elucidate the mechanism by which 
statin drugs (HMG-CoA reductase inhibitors) cause the sequestration of G protein-
coupled receptors (GPCRs) in the endocytic recycling compartment (ERC).  Specifically, 
we examined the effects of statin drugs on the trafficking of the LPA1 lysophosphatidic 
acid receptor (LPA1R). 
 Membrane trafficking of GPCRs, to and from the plasma membrane, regulates 
their surface abundance, which in turn, contributes to the sensitivity of cells towards 
agonists.  Although much is known about the internalization and desensitization of 
GPCRs, very little is known about the recycling of GPCRs from endosomes back to the 
plasma membrane.  LPA1Rs are normally present on the surface of the cell.  After 
binding to lysophosphatidic acid (LPA), the receptor tranduces the signal to 
heterotrimeric G proteins present inside the cell.  These G proteins then activate 
downstream signaling pathways within the cell that result in effects, such as the 
stimulation of cell proliferation.  The LPA1R is then internalized to early endosomes, and 
then transits to recycling endosomes from which it is normally recycled back to the cell 
surface. 
 Our initial findings were that HMG-CoA reductase inhibitors (atorvastatin and 
mevastatin) induce the sequestration of the G protein-coupled LPA1R in recycling 
endosomes, most likely by inhibiting the recycling of tonically (in the absence of LPA 
stimulation) internalized receptors.  Atorvastatin also induced sequestration of β2-
adrenergic receptors and M2 muscarinic acetylcholine receptors.  Whereas, co-addition of 
 xiii
geranylgeranylpyrophosphate (GGPP) or geranylgeraniol (GGOH) prevented 
atorvastatin-induced sequestration of LPA1Rs, the geranylgeranyltransferase-I inhibitor, 
GGTI-298, mimicked atorvastatin and induced LPA1R sequestration.  This suggested that 
statin-induced endosomal sequestration was caused by defective protein prenylation.  The 
likely targets of atorvastatin and GGTI-298 are the Rho family GTPases, RhoC and 
RhoA, since both inhibitors greatly reduced the abundance of these GTPases and since 
knockdown of endogenous RhoC or RhoA with small interfering RNAs (siRNAs) led to 
endosomal sequestration of LPA1R.  Knockdown of RhoC was much more potent at 
inducing endosomal sequestration than knockdown of either RhoA or RhoB.  In contrast, 
atorvastatin, GGTI-298, siRNA against RhoA, B, or C did not alter the internalization or 
recycling of transferrin receptors, indicating that recycling of transferrin receptors is 
distinct from LPA1Rs.  Thus, these results, for the first time, implicate RhoA and RhoC 
in endocytic recycling of LPA1Rs and identify atorvastatin and GGTI-298 as novel 
inhibitors of this process. 
 Future studies will likely reveal specific effector proteins that interact with RhoA 
and RhoC.  These effectors may be involved with sorting the receptors, pinching off 
transport vesicles, or tethering the vesicles to motor proteins that will transport them back 
to the cell surface. 
 
 
CHAPTER I 
INTRODUCTION 
G protein-coupled receptors (GPCRs) 
Background Qn GPCRs 
The largest group of signaling receptors in mammalian cells is the G protein-
coupled receptors (GPCRs). GPCRs participate in a wide variety of physiological 
processes including sensing of the external environment (including sight, smell, and 
taste), neurotransmission, muscle contraction, and mitogenesis (Lefkowitz, 2000). 
GPCRs undergo a conformational change upon binding to a ligand, which leads to 
association with and activation of heterotrimeric G proteins (Figure I, Step l ). In Step 2, 
desensitization limits the extent of G protein stimulation, wherein most GPCRs are 
rapidly phosphorylated by G protein receptor kinases (GRKs) or by second messenger 
kinases (Benovic et al., 1987). ~-arrestins bind to the GRK-phosphorylated GPCRs and 
block G proteins from interacting with and binding to the desensitized GPCR (Figure l, 
Step 2) (Ahn et al., 2003). Most GPCRs are then transported into cells through endocytic 
pathways (Figure I, Step 3) and proceed to early endosomes from which they are either 
sorted to lysosomes for degradation (down-regulation; Figure I, Step 4) or are de-
phosphorylated and transported to recycling endosomes to be recycled back to the plasma 
membrane for further signaling (resensitization; Figure I, Step 5) (Lin et al., 200 I; Zhang 
et al., 1997). Many GPCRs undergo a low basal rate of endocytosis and recycling even 
in the absence of stimulating ligands (Ferguson, 2001). 
Errata - p. 2 
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Figure 1: Overall model of GPCR regulation. 
(1) Ligand binding and activation of heterotrimeric G proteins.  (2) β-arrestin binding and 
desensitization.  (3) Endocytosis.  (4) Degradation in lysosomes (down-regulation).  (5) 
Recycling back to the plasma membrane for further signaling (resensitization). 
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There are over 800 genes in the human genome that encode GPCRs, and although 
many studies have been performed there is much that is yet to be discovered about the 
detailed functional mechanisms of GPCRs (Wolfe and Trejo, 2007). The structure of the 
GPCR comprises an extracellular N-terminal domain, seven transmembrane domains 
connected by three intracellular and three extracellular loops, and an intracellular C-
terminal domain (Pitcher et al., 1998). The complex structures of GPCRs allow these 
versatile receptors to recognize and interact with a wide variety of molecules both within 
the cell and outside the cell. 
GPCR end_ocytic trafficking overview 
The movement of GPCRs through the cell is a complex process with delicate 
regulation. The pathways for endocytosis can be divided into three main categories, 
clathrin-dependent endocytosis, caveolae-dependent endocytosis, and finally other 
pathways that are independent of both clathrin and caveolae. The first type of 
endocytosis discovered was clathrin-dependent endocytosis, in which vesicles coated 
with clathrin bud from and are pinched off from the cell surface. The clathrin coats have 
a role in packaging the GPCRs or other cargo while also providing a structural shape to 
the vesicle. Thus, there is a connection between the sorting of the cargo and the 
packaging of the cargo in clathrin-dependent endocytosis (Schmid, 1997). 
The proper functioning of GPCRs depends on precise and well controlled 
membrane trafficking. GPCR trafficking controls processes including receptor down-
regulation, receptor internalization, receptor signaling from intracellular compartments, 
and receptor resensitization via recycling to the plasma membrane from endosomes 
(Ferguson, 2001). GPCRs are rapidly desensitized after agonist stimulation through 
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mechanisms involving receptor phosphorylation and, in many cases, through association 
with the multi-functional scaffolding proteins, J3-arrestins (Benovic et al., 1987; Zhang et 
al., 1997). The internalization of many GPCRs occurs through both clathrin-independent 
endocytosis and clathrin-dependent endocytosis. After leaving the early endosomes, 
GPCRs are either sorted to lysosomes for degradation (down-regulation) or can be 
dephosphorylated and recycled back to the plasma membrane via recycling endosomes. 
Lysosomal sorting ofGPCRs is signaled for by ubiquitylation of the receptors (Shenoy et 
al., 2001; Shenoy and Lefkowitz, 2003). Some GPCRs that have type I PDZ binding 
domains in their cytoplasmic tails are sorted for rapid recycling by binding to their target 
PDZ-containing proteins (Cao et al., 1999; Gage el al., 2005). However, not all GPCRs 
have PDZ binding domains, so other methods of GPCR recycling must be occurring. 
There are two main endocytic recycling pathways (Maxfield and McGraw, 2004). 
The first, 'fast', pathway is responsible for recycling of proteins from early endosomes to 
the plasma membrane and is regulated by the small GTPase, Rab4 (van der Sluijs et al., 
1992). The second, 'slow', pathway routes proteins through pericentriolar recycling 
endosomes on their way back to the plasma membrane (Sheff et al., 1999; Maxfield and 
McGraw, 2004). The recycling endosomes also serve as a direct access point for 
endocytic cargo to the trans-Go1gi network (TGN) and to the secretory pathway (Ghosh 
et al., 1998; Mallard et al., 1998). Recycling endosomes are normally identified by the 
presence of transferrin receptor (TfnR) and the lack of other cargo, such as low density 
lipoprotein, which is destined for degradation in lysosomes (Sheff el al., 1999; Maxfield 
and McGraw, 2004). 
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Clathrin~dependent -~ndocytosis 
Most receptors at the cell surface are internalized through clathrin-dependent 
endocytosis pathways. Clathrin heavy-chain and clathrin light-chain molecules form a 
structural framework for the clathrin-coated pit, which is then pinched off from the cell 
surface plasma membrane by dynamin. The assembly of the clathrin-coated pit is 
facilitated by various accessory proteins and adaptor proteins, which act to sort specific 
cargo into the clathrin-coated vesicle. Adapter protein-2 (AP-2) is one of the key 
adaptors for clathrin-coated vesicles. AP-2 recognizes short dileucine-based and 
tyrosine-based portions of proteins, but other signals also guide proteins into clathrin-
coated vesicles, which implicate additional adaptors sorting distinct cargo into the 
pathway (Wolfe and Trejo, 2007). 
A high level of regulation of clathrin adaptors is indicated in part by observations 
that the adaptor proteins are themselves ubiquitinated and phosphorylated. Non-visual 
arrestins were the first adaptors identified with an involvement in clathrin-dependent 
endocytosis. AP-2 and clathrin interact with non-visual arrestins in the endocytosis of 
desensitized GPCRs. Two non-visual arrestins, ~-arrestinl and ~-arrestin2, are key 
participants in the clathrin-dependent endocytosis of GPCRs. The binding of ~-arrestinl 
and ~-arrestin2 to desensitized GPCRs displaces the G proteins and aids in the formation 
of clathrin-coated pits. ~-arrestinl and ~-arrestin2 have an amino-terminal antiparallel ~­
sheet region connected by a core of 12 polar amino acids to a carboxy-terminal 
antiparallel ~-sheet region. The polar amino acids of the core interact with the 
phosphorylated portions of the desensitized GPCR. GPCR binding exposes the carboxy-
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terminal antiparallel P-sheet region that interacts with the heavy-chain of clathrin (Wolfe 
and Trejo, 2007). 
Two major classes ofGPCRs 
There are two major classes of GPCRs, class A receptors and Class B receptors. 
Class A receptors bind to P-arrestin2 more strongly than to P-arrestin I, and class A 
receptors do not interact with visual arrestins. Some examples of class A receptors are 
dopamine DIA receptors, alb adrenergic receptors, mu opioid receptors, p2 adrenergic 
receptors, and endothelin type A receptors. Class B receptors bind to both p-arrestin2 
and P-arrestinl with equally high strength, and class B receptors do interact with visual 
arrestins. Some examples of class B receptors are substance P receptors, vasopressin V2 
receptors, angiotensin II type I A receptors, thyrotropin-releasing hormone receptors, and 
neurotensin receptor I. It was found that swapping the carboxyl-terminal segments of 
class A receptors and class B receptors also completely switched their respective binding 
affinities. It was also found that, swapping the carboxyl-terminal segments of p-arrestin2 
and P-arrestin I swapped their cellular localization and swapped their binding affinity for 
class A receptors. Furthermore, it was shown that GPCRs other than rhodopsin can 
interact with visual arrestins. These observations point to the signaling of GPCRs being 
differentially regulated depending on the relative amounts of different arrestins and the 
interactions of other proteins with the different arrestins (Oakley et al., 2000). 
GP(:R structun)l features and i[lJeractions 
Relatively short sequences in the cytosolic portions of GPCRs predominately 
facilitate their trafficking to endosomes and lysosomes. Distinct protein coat components 
are targeted to distinct sequences present in GPCRs. Adaptor proteins AP-I, -2, -3, and -
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4, bind to the sequences [DE]XXXL[LI] and YXXO. NPXY sequences interact with AP-
2, clathrin, and Dab2 (disabled homolog 2, mitogen-responsive ), and AP-2 subunit mu2 
interacts with the sequences DXXLL and YXXO. The binding of these target sequences 
can be further modulated by the sequences being ubiquitinated or phosphorylated. 
Ubiquitinated GPCRs are trafficked to the lysosomes for degradation (Bonifacino and 
Traub, 2003). 
LP A (lysophosphatidic acid) and LP A receptors 
General proner1jes of LPA 
Lysophosphatidic acid (LPA) (l-acyl-2-lyso-sn-glycero-3-phosphate) 1s a 
naturally occurring phospholipid growth factor that comprises a lone fatty acyl chain 
attached to a backbone of glycerol bound to a phosphate group (van Leeuwen et al., 
2003). LPA stimulates specific G protein coupled receptors (GPCRs), which then 
activate the G;, Gq, and 0 12113 families of heterotrimeric G proteins (Ishii et al., 2000). 
Some of the intracellular processes stimulated by LP A include: intracellular calcium 
release (Jalink et al., 1995), activation of the Rho GTPase (Ridley and Hall, 1992), 
transcriptional activation of serum-responsive genes (Hill et al., 1995), and activation of 
the MAP kinase cascade (van Corven et al., 1992). At the cellular level, LP A can 
stimulate processes as diverse as neurite retraction (Ishii et al., 2000), smooth muscle 
contraction (Toews et al., 1997), and cell proliferation. LPA was first shown to stimulate 
the proliferation of fibroblasts in a G-protein dependent fashion (van Corven et al., 1992). 
In addition to fibroblasts, LPA potently stimulates the growth of a variety of tumor cells 
including cells derived from: ovarian cancer (Xu et al., 1995), prostate cancer (Kue et al., 
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2002), and breast cancer (Xu et al., 1995). The many responses to LPA are mediated by 
specific receptors for LP A. 
L_? A production and degradation 
LPA can be produced multiple ways within the cell. One method for the 
production of LPA involves phospholipase Al or A2 (PLA I or PLA2) processing 
phosphatidic acid by removing a fatty acyl chain. Cleavage of fatty acids at the sn-1 
position of a phospholipid is performed by PLAl, whereas cleavage of fatty acyl chains 
at the sn-2 position of a phospholipid is performed by PLA2. The 125 kDa 
transmembrane protein ATX/lyso phospholipase D (A TX/lysoPLD) was first discovered 
as an autocrine motility factor produced by human melanoma cells. A TX/lysoPLD can 
generate LPA from membrane phosphatidylcholine by the removal of choline. Several 
cancers have been observed to have increased A TX/lysoPLD levels compared to normal 
cells, such as neuroblastoma, hepatocellular carcinoma, mammary carcinoma, renal-cell 
carcinoma, and non-small-cell lung carcinoma. The finding that secreted A TX/lysoPLD 
is a tumor motility factor increases the understanding of the involvement of LPA m 
cancer progression and initiation (Mills and Moolenaar, 2003). 
In order to maintain the delicate balance of a properly functioning cell, the 
production of LPA needs to be complimented with pathways for LPA degradation. One 
possible partial control mechanism is that LPA production by A TX/lysoPLD is very well 
controlled, so as not to allow LPA concentrations to exceed necessary levels in the first 
place. However, degradation of LP A is a much more direct counterbalance to LPA 
production. LPA is quickly dephosphorylated and converted to monoacylglycerol. Lipid 
phosphate phosphohydrolases (LPPs) are integral membrane proteins that 
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dephosphorylate LPA. At least four LPPs have been identified, and each has six 
transmembrane segments. Not surprisingly, the expression of LPPs is observed to be 
lower in ovarian cancer cells compared to normal cells. Thus, increasing LPP expression 
could be useful as an anti-cancer treatment for ovarian cancer and other cancers that may 
have decreased LPP expression (Mills and Moolenaar, 2003). 
LP A receptors 
The first LPA receptor was cloned from a screen for heptahelical receptors that 
were enriched in embryonic brain cortex; this receptor is now known as LPA 1R and is the 
most widely expressed LPA receptor (Ishii et al., 2000). In addition to LPA 1R, two other 
closely-related LPA-specific receptors, LPA2R and LPA1R, the more distantly-related 
LP A4R, and the recently characterized LP A5R, comprise the known heptahelical LP A 
receptors (Lee et al., 2006). It has also been shown that the nuclear receptor PPAR-y is a 
high affinity LPA receptor (Mills and Moolenaar, 2003). 
The variety of downstream signaling effects of LPA is due to the ability of LPA 
receptors, specifically LPA1R, LPA2R, and LPA3R to interact with three different G 
proteins, Gi, Gq, and 0 12113 • Activation of Gi feeds into three main signaling pathways, 
stimulation of phosphatidylinositol 3-kinase (PI3K), activation of Ras-mitogen-activated 
protein kinase (Ras-MAPK), and inhibition of adenylyl cyclase that results in decreased 
cyclic AMP concentration within the cell. Activation of Gq subsequently activates 
phospholipase C (PLC). Activation of PLC results in the hydrolysis of 
phosphatidylinositol-bisphosphate and generates second messengers that change the 
concentration of calcium in the cytosol and activate protein kinase C (PKC). Activation 
ofG 12113 results in the activation ofRhoA (Mills and Moolenaar, 2003). 
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LPA1R and LPA2R were found to mediate cell rounding induced by LPA, 
whereas LPA3R was found to result in neurite elongation in B 103 neuroblastoma cells 
and actually inhibited cell rounding in TR mouse neuroblastoma cells. LPA 1R, LPA2R, 
and LPA1R were found to mediate inhibition of adenylyl cyclase and to mediate PLC 
activation. In addition, LPA 1R, LPA2R, and LPA3R were found to mediate arachidonic 
acid release and MAPK activation (Ishii et al., 2000). 
Although LPARs have been well studied, relatively little is known about the 
cellular mechanisms that regulate the number of LPA receptors present on the surface 
plasma membrane of cells. 
Prenylated proteins 
Overv_ie~ of preny la ti on 
Proteins, including RhoA, B, and C, that contain a carboxyl-terminal CAAX box 
(wherein CAAX represents a chain of a cysteine, an aliphatic amino acid, an aliphatic 
amino acid, and any amino acid) require posttranslational processing to facilitate proper 
function and localization (Adamson et al., 1992). Prenylation is the process by which 
proteins are covalently modified with a hydrophobic chain of prenyl (3-methylbut-2-en-
l-yl) groups that facilitate interactions with membranes and mediate interactions with 
other proteins (Casey and Seabra, 1996). RhoC and A are geranylgeranylated by 
geranylgeranyltransferase type-I (GGTase-I) (Collisson et al., 2003; Casey and Seabra, 
1996). 
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Rho proteins 
RhoA, B, and C are members of the Rho family of GTPases. The Rho family of 
GTPases also encompasses Cdc42 and Rael. Cdc42 (cell division cycle 42) regulates 
cell signaling pathways that control a variety of cellular functions including endocytosis, 
cell migration, cell morphology, and cell cycle progression. Cdc42 regulates the bipolar 
attachment of spindle microtubules to kinetochores during metaphase of the cell cycle. 
Cdc42 also is involved in the formation and extension of filopodia, which are thin, actin-
rich surface projections that pull migrating cells forward (Bishop and Hall, 2000). Rae 1 
(Ras-related C3 botulinum toxin substrate I) is ubiquitously expressed and regulates a 
variety of cellular functions including cell adhesion, cell differentiation, cytoskeletal 
reorganization, the control of cell growth, and the activation of protein kinases (Hajdo-
Milasinovic et al., 2007). 
The rho genes were first identified from a cDNA library of the sea slug Aplysia. 
The homology between Aplysia and human Rho proteins was found to be greater than 
85%. The rho gene products and ras gene products both have segments of strong internal 
homology, both are approximately 21 kDa, and both possess carboxy-terminus sequences 
required for membrane attachment. These similarities suggest that Rho and Ras may 
have common functions, but may carry out those functions through different mechanisms 
(Madaule and Axel, 1985). The three human Rho proteins were later denoted RhoA, B, 
and C, and it was found that all three are modified by C3 transferase from C. botulinum. 
An early study found that micro injection of RhoA into fibroblasts resulted in an increase 
in actin stress fibers (Ridley, 2001). Interestingly, it was found that LPA is a serum 
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component that is responsible for Rho-mediated stress fiber formation (Ridley and Hall. 
1992). 
The localization, trafficking, and functioning of the ras family of proteins relies 
on modifications to the proteins made after translation. The CAAX box (wherein CAAX 
represents a chain of a cysteine, an aliphatic amino acid, an aliphatic amino acid, and any 
amino acid) of the ras proteins can be carboxymethylated or prenylated. RhoA, B, and C 
are members of the ras family and are carboxymethylated at the carboxy-terminus. RhoB 
is modified with farnesyl (15 carbon) or geranylgeranyl (20 carbon) groups. A mutation 
in the CAAX box ofp2lrhoB of the cysteine at 193 prevented prenylation. Additional 
mutational studies of p2 l rhoB found that sites at cysteine 189 and cysteine 192 found 
that those locations are necessary for palmitoylation (Adamson et al., 1992). 
The three human Rho genes were found to be located on separate chromosomes, 
with RhoA found on 3p21, RhoB found on 2p12, and RhoC found on 5q31 (Cannizzaro 
et al., 1990). A later study determined that the gene for RhoC was likely generated by an 
incomplete duplication of the gene for RhoA. It was also determined that the gene for 
RhoB was likely the result of reverse transcription (Karnoub et al., 2004). RhoB was 
shown to be a rather unstable protein. In He La cells and PC 12 (rat adrenal medulla 
pheochromocytoma) cells, RhoB production is rapidly and transiently induced and varies 
throughout the stages of the cell cycle. The relative amount of RhoB present peaks 
during synthesis phase (S-phase) of the cell cycle, and then decreases during the 
transition from S-phase to Gap 2 (G2) and mitosis (M) phases of the cell cycle. In 
addition, a perinuclear localization was observed for growth factor induced RhoB protein. 
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These findings indicated that RhoB is involved in S-phase and/or in the transition 
between Gap I (G1) phase and S-phase of the cell cycle (Zalcman et al., 1995). 
Guanine nucleotide exchange factors (GEFs) stimulate the exchange of GDP for 
GTP to generate the active forms of RhoA, B, and C that then interact with effectors and 
other downstream targets. This downstream communication is then turned off by 
GTPase activating proteins (GAPs) that stimulate deactivation of RhoA, B, and C. The 
relative number of Rho GEFs has been found to exceed the number of Rho proteins by a 
factor of three. It is possible that different receptors utilize different GEFs to activate a 
specific GTPase. This indicates that a specific GEF links many different receptors to the 
activation of Rho proteins. Deletions and rearrangements of genes encoding Rho GEFs 
have been identified in cases of cancer, neurodegenerative disorders, and developmental 
disorders. The cytosolic or membrane localization of RhoA, B, and C is regulated by 
guanine nucleotide dissociation inhibitors (GD!s). Inactive (GDP-bound) Rho proteins 
have a cytosolic localization and are bound to Rho GD!s. For activation of the Rho 
protein to occur, the Rho GD! must be released from the Rho protein (Schmidt and Hall, 
2002). 
Pharmacological agents that affect prenylation 
HMG-CoA reductase inhibitors (statin~ 
The statins are a class of compounds that inhibit HMG-CoA reductase and are 
mainly used to lower blood cholesterol concentrations (Veillard and Mach, 2002). 
Statins inhibit the rate limiting step of the cholesterol synthesizing mevalonate pathway, 
which also yields ubiquinones, dolichols, sterol, farnesylpyrophosphate (FPP), and 
geranylgeranylpyrophosphate (GGPP) (Chan et al., 2003). Atorvastatin, a widely 
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prescribed statin marketed by Pfizer as Lipitor, was found to inhibit the activation of Rho 
proteins and inhibit metastasis of melanoma cells exhibiting RhoC overexpression 
(Collisson et al., 2003). 
Geranylgeranyltransferase and Farnesylt~~sferase lnhibitors{QGT!s ancl_FJ!s) 
GGTI-298 and FTI-277 are compounds that mimic the CAAX box protein 
sequence. GGTI-298 inhibits geranylgeranyltransferase I (GGTase I) and FTI-277 
inhibits farnesyltransferase (FTase) (Lerner el al., 1995; Vogt et al., 1996). The 
compound FTI-277 is a potent inhibitor of oncogenic Ras processing and signaling 
(Lerner et al., 1995). GGTI-298 has been shown to block PDGF- and epidermal growth 
factor-dependent tyrosine phosphorylation of their corresponding tyrosine kinase 
receptors, whereas inhibition of protein farnesylation with FTI-277 has no effect on 
receptor tyrosine kinase phosphorylation (McGuire et al., 1996). GGTI-298 was found to 
inhibit the growth of human tumors in nude mice (Sun et al., 1998). The mechanism for 
this activity may be similar to the GGTI-298-mediated G1 phase block and subsequent 
apoptosis in cultured human tumor cells (Miquel et al., 1997). GGTI-298 also induces 
G1 arrest and apoptosis in rat pulmonary artery smooth muscle cells. Furthermore, 
GGTI-298 inhibited the ability of PDGF, interleukin-I beta, and activated Ras to induce 
superoxide production in smooth muscle cells (Stark et al., 1998). In summary, GGTI-
298 has antiproliferative effects on fibroblasts, epithelial, and smooth muscle cells, which 
appear to be mediated by arrest of G1 phase (Vogt et al., 1997). 
Treatment of human cancer cells, including bladder, lung, colon, brain, and breast 
cancers, with GGTI-298 and FTl-277 results in increased RhoB expression. Induction of 
RhoB takes place at the transcriptional level. Actinomycin D was found to prevent this 
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induction of RhoB. Treatment of cancer cells with GGTI or FT! resulted in the 
separation of histone deacetylase I (HDACI ), binding of hi stone acetyltransferase 
(HAT), and resulted in acetylated histones in the promoter region of RhoB. These results 
show that the level of RhoB expression, in cells treated with GGTI or FT!, is modulated 
by the acetylation of the RhoB promoter (Delarue et al., 2007). 
Regulation of LPA1R Trafficking 
We have been studying the trafficking of the most widely expressed GPCR for the 
bioactive lipid lysophosphatidic acid (LPA), the LPA1R. LPA is an abundant serum 
lysophospholipid that evokes growth factor-like responses through GPCR activation. 
LPA promotes cell growth and survival (van Carven et al., 1992; Fang et al., 2000; 
Goetz! et al., 2000), causes cytoskeletal rearrangements (Ridley and Hall, l 992), 
stimulates serum-responsive genes (Hill et al., 1995), and promotes cancer progression 
(Hama et al., 2004; Kue et al., 2002; Mills and Moolenaar, 2003; Mukai et al., 2000; 
Stam et al., 1998; Xu el al., 1995;). LPA activates at least five distinct GPCRs, which 
collectively can activate Gs, G;, f3y, Gq, and G 12m signaling pathways (Meyer zu 
Heringdorf and Jakobs, 2007). LPA 1Rs are internalized in response to LPA stimulation 
through a pathway that depends on clathrin and f3-arrestin (Wang et al., 2001; Murph et 
al., 2003; Urs et al., 2005). However, unlike other GPCRs, LPA1Rs require membrane 
cholesterol to associate with f3-arrestins (Urs et al., 2005). Once internalized, LPA1Rs 
transit through early endosomes and localize to recycling endosomes, wherein they 
extensively colocalize with transferrin receptors (Murph et al., 2003). The removal of 
LPA results in a rapid recycling ofLPA1Rs from recycling endosomes back to the plasma 
membrane. Our present results from studying the effects of statins and preny lation 
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inhibitors on the membrane trafficking of the LPA1Rs implicate RhoC and RhoA, in the 
regulation of LPA1R recycling from endosomes through a mechanism that is distinct 
from that utilized by transferrin receptor recycling pathway. The results of these studies 
will be described in detail below. 
Errata - p. 16 
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CHAPTER 2 
MATERIALS AND METHODS 
Antibodies and reagents 
 Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate; LPA) was 
purchased from Avanti Polar Lipids (Alabaster, AL).  FLAG-tagged LPA1R receptors 
were detected with mouse anti-M1 FLAG or rabbit anti-FLAG antibodies (Sigma 
Chemical Co., St. Louis, MO).  HA-tagged β2ARs and HA-tagged LPA1Rs were detected 
with mouse anti-HA antibodies (Covance, Berkeley, CA).  Anti-transferrin receptor 
mouse monoclonal antibody (clone B3/25) was from Boehringer Mannheim (Mannheim, 
Germany).  The mouse anti-LAMP-1 antibody was obtained from the Developmental 
Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by 
The University of Iowa, Department of Biological Sciences (Iowa City, IA).  Anti-EEA1 
was from BD Biosciences (San Jose, CA).  Rat monoclonal antibody against human M2 
mAChRs was obtained from Chemicon, Inc. (Temecula, CA).  Cy2- and Cy3-conjugated 
goat anti-mouse IgG, goat anti-rabbit IgG, goat anti-rat IgG, anti-human golgin-97 mouse 
monoclonal antibody, and Hoechst 33342 were purchased from Molecular Probes, Inc 
(Eugene, OR).  Atorvastatin calcium was obtained from JMar Chemical Co. (Englewood, 
CO), prepared as a 10 mM solution in DMSO, and stored at -80 °C.  Mevastatin was 
purchased from Tocris (Ellisville, MO) and was prepared as a 10 mM solution in DMSO 
and stored at -80 °C.  Geranylgeranyltransferase inhibitor (GGTI-298) and 
farnesyltransferase inhibitor (FTI-277) were from Calbiochem (La Jolla, CA).  These 
compounds were prepared as 20 mM solutions in DMSO and stored at -80 °C.  
Farnesylpyrophosphate (FPP), geranylgeranylpyrophosphate (GGPP), and ubiquinone 
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from Sigma Chemical Co. were dissolved in methanol and stored at -20 °C.  Myo-[3H] 
inositol was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO).  
All other reagents were obtained from Sigma Chemical Co., unless otherwise specified. 
Cell culture and DNA transfection 
 LPA1R/HeLa cells, which stably-express FLAG-tagged or HA-tagged human 
LPA1R, and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 I.U./ml penicillin, 100 µg/ml 
streptomycin (Media Tech, Inc, Herndon, VA), and 1mM sodium pyruvate (Biosource 
International, Camarillo, CA) at 37 °C with 5% CO2.  Cells were grown on glass 
coverslips (for immunolocalization) and transfected in six-well dishes, or were grown in 
24-well dishes for myo-[3H] inositol labeling.  Transient transfections were performed 
using ExGen 500 (Fermentas Inc., Hanover, MD), according to the manufacturer’s 
directions.  Plasmids encoding M2 mAChRs were transiently transfected into 
LPA1R/HeLa cells at one µg/well (6-well dish).  Plasmids encoding HA-tagged β2AR 
were transfected at 1 µg/well (6-well dish) (Kim and Benovic, 2002; Paing et al., 2002).  
Cells were incubated in serum free DMEM supplemented with 1mM sodium pyruvate 
(SFM) for 24 prior to immunolocalization.  All drug treatments were performed in SFM 
with the medium and treatments refreshed every 24 h.  For transient transfection 
experiments, statins and prenylation inhibitors were present from the start of transfection. 
Indirect immunofluorescence 
 Cells were treated as described in the figure legends, 24-48 h after transfection.  
Cells were then fixed in 2% formaldehyde in phosphate buffered saline (PBS) for 10 
min., and rinsed with 10% fetal bovine serum (FBS) containing 0.02% azide in PBS 
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(PBS-serum).  Fixed cells were incubated with primary antibodies diluted in PBS-serum 
containing 0.2% saponin for 1 h, and then washed (3 times, 5 min each) with PBS-serum.  
The cells were then incubated with fluorescently labeled secondary antibodies diluted in 
PBS-serum containing 0.2% saponin for 1 h, washed three times with PBS-serum, 
washed once with PBS, and mounted on glass slides as previously described (Murph et 
al., 2003).  All images were acquired using an Olympus BX40 epifluorescence 
microscope equipped with a 60x Plan pro lens and photomicrographs were prepared using 
an Olympus MagnaFire SP digital camera (Olympus America Inc., Melville, NY).  
Images were processed using Adobe Photoshop 6.0 (Adobe Systems Inc., San Jose, CA). 
Quantification of LPA1R colocalization with TfnR 
 LPA1R/HeLa cells were grown on glass coverslips and treated as described in the 
figure legends.  The cells were then rinsed with PBS, fixed with 2% formaldehyde in 
PBS, and processed for immunofluorescence localization of LPA1R using rabbit anti-
FLAG and TfnR using mouse anti-TfnR, followed by Cy2- and Cy3- conjugated 
secondary antibodies. The extent of LPA1R colocalization with TfnR was determined by 
quantifying the extent of pixel colocalization of LPA1R staining with TfnR fluorescence 
using Metamorph Imaging software (Urs et al., 2005).  The background was subtracted 
from unprocessed images and the percentage of LPA1R pixels that overlapped with TfnR 
pixels was measured.  The data presented is the mean ± s.e.m. of the indicated number of 
cells per sample obtained from a representative experiment that was performed three 
independent times with similar results. 
 32
Antibody internalization assay 
 HeLa cells stably expressing HA-tagged LPA1Rs were either pretreated with 
vehicle (DMSO) or with atorvastatin (10 μM) for 24 h, chilled to 4°C, and incubated for 
30 min with 2.5 µg/ml anti-HA antibodies diluted in serum-free medium.  Excess 
antibodies were removed by washing with serum-free medium.  For untreated cells and 
cells pre-treated with atorvastatin, these samples were warmed to 37°C in the presence of 
atorvastatin (10 μM) for an additional 24 hr.  For GGTI-298-treated samples, these cells 
were warmed to 37°C for 4 hours with 20 μM GGTI-298.  Following treatments at 37°C, 
antibodies bound to the cell surface were removed by rinsing the cells with 100 mM 
glycine, 20 mM magnesium acetate, 50 mM KCl, pH 2.2 (acid wash) (Naslavsky et al., 
2004b) for 90 seconds, while retaining internalized antibody.  The cells were then fixed 
in 2% formaldehyde in PBS and mounted on glass slides. Images were taken using a 
Hamamatsu digital camera mounted on a Leica Inverted microscope with a 63X oil 
immersion objective. The images were analyzed by Simple PCI software (Compix, 
Cranberry Township, PA) and total fluorescence (vesicles/cell) for both internalized and 
surface antibody levels were measured as described previously (Xiao et al., 2005). 
Internalization (fluorescence after acid wash) is expressed as a percentage of total 
fluorescence of initial surface bound antibodies (4°C). 
Transferrin recycling 
 LPA1R/HeLa cells were plated on glass coverslips and treated as indicated.  
Following treatment, cells were loaded with Alexa 546-transferrin (20 μg/mL) 
(generously provided by Dr. Fred Maxfield (Weill Medical College of Cornell 
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University, New York, NY)) for 30 min. at 37 °C.  Loading was terminated with two 
washes in mild acid buffer (50 mM 2-(N-morpholino)ethanesulfonic acid, 280 mM 
sucrose, pH 5.0, 37 °C), and four washes in SFM (Presley et al., 1993).  The cells were 
then incubated at 37 °C in chase medium (SFM containing 0.5 mg/mL unlabeled Tfn and 
20 μM desferroxamine) for various periods.  Following the chase, cells were washed 
twice in mild acid buffer, washed four times with SFM, and fixed in 2% formaldehyde in 
PBS for 10 min.  Cells were then washed once with PBS and mounted on glass slides.  
Integrated fluorescence intensity per cell was quantified using Metamorph Imaging 
software (Universal Imaging, West Chester, PA). 
Phosphoinositide hydrolysis 
 LPA1R/HeLa cells were plated at a density of 4.0 × 104 cells/well into 24-well 
plates.  At 24 h post-transfection, cells were labeled overnight with myo-[3H] inositol in 
inositol- and serum-free medium, treated as described in the figure legends, and then 
processed for analysis of phosphoinositide hydrolysis by anion exchange 
chromatography, as described (Paing et al., 2002; Urs et al., 2005). 
Membrane and cytosol fractionation 
 LPA1R/HeLa cells were grown in 10 cm dishes.  Following treatment, cells were 
rinsed twice with ice cold PBS on ice/water bath.  Cells were then scraped into 4 mL of 
ice cold PBS.  Cells were pelleted for 5 min. at 300×g at 4 °C, resuspended in 1 mL of 
250 mM sucrose, 10 mM Tris-Cl (pH 7.4), and pelleted again for 5 min. at 300×g at 4 °C.  
Cells were resuspended in 0.5 mL of 100 mM sucrose, 10 mM Tris-Cl (pH 7.4), and then 
broken by passing the suspension through a 25 gauge syringe needle 15 times.  The 
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suspension was then centrifuged for 10 min. at 800×g at 4 °C (Song et al., 1998).  
Postnuclear supernatant (PNS) was then transferred to a chilled tube and protein content 
was determined by BCA Protein Assay.  Exactly 50 μg of PNS from each sample was 
centrifuged for 30 min. at 100,000×g at 4 °C .  The supernatant was removed and mixed 
with an appropriate volume of 4× SDS sample buffer.  The pellet was solubilized in an 
equal volume of 1× SDS sample buffer.  Samples were incubated for 5 min. at 95 °C 
prior to separation of equal volumes by SDS-PAGE and immunoblotting. 
Immunoblotting 
 Following treatment, cells were solubilized by addition of lysis buffer (1% NP-40, 
1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate pH 7.2, 2 
mM EDTA, 50 mM NaF, 0.2 M sodium orthovanadate, 0.02% azide, 100 µg/ml 
leupeptin and 0.1 mM PMSF) .  The samples (12 µg protein per lane) were then separated 
by 10% SDS-PAGE and transferred to nitrocellulose.  Detection of HRP-conjugated 
secondary antibodies was performed with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce Biotechnology), followed by exposure to Kodak BioMax Light Film.  
Films were scanned on a flatbed scanner and bands were quantified using Metamorph 
Imaging software. 
RNA interference 
 Cells were transfected using Lipofectamine™ RNAiMAX Reagent in Opti-
MEM® I Reduced Serum Medium (Invitrogen, Carlsbad, CA).  Stealth™ Select 3 RNAi 
Sets directed against RhoA, RhoB, or RhoC (Table 1) were used as instructed by the 
manufacturer (Invitrogen).  The cells were transfected a second time, as above, and the 
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medium was then replaced with SFM and incubated for an additional 24 hours before 
experimentation.  Medium GC Stealth™ RNAi Negative Control Duplexes (Cat. # 
12935-300) were used as instructed by the manufacturer (Invitrogen).  Transfection 
efficiency of over 80% was confirmed by cotransfection of cells with BLOCK-iT™ 
Fluorescent Oligo (Invitrogen). 
 36
 
Table 1: Sequences of siRNAs directed against RhoA, RhoB, or RhoC. 
  Sequence 
siRhoA 1 Sense GCCUGUGGAAAGACAUGCUUGCUCA 
siRhoA 1 Antisense UGAGCAAGCAUGUCUUUCCACAGGC 
siRhoA 2 Sense ACCCAGAUACCGAUGUUAUACUGAU 
siRhoA 2 Antisense AUCAGUAUAACAUCGGUAUCUGGGU 
siRhoA 3 Sense CAGCAAAGACCAAAGAUGGAGUGAG 
siRhoA 3 Antisense CUCACUCCAUCUUUGGUCUUUGCUG 
siRhoB 1 Sense CGUGCCUGCUGAUCGUGUUCAGUAA 
siRhoB 1 Antisense UUACUGAACACGAUCAGCAGGCACG 
siRhoB 2 Sense GUCUUCGAGAACUAUGUGGCCGACA 
siRhoB 2 Antisense UGUCGGCCACAUAGUUCUCGAAGAC 
siRhoB 3 Sense ACACCGACGUCAUUCUCAUGUGCUU 
siRhoB 3 Antisense AAGCACAUGAGAAUGACGUCGGUGU 
siRhoC 1 Sense GCAAGGAUCAGUUUCCGGAGGUCUA 
siRhoC 1 Antisense UAGACCUCCGGAAACUGAUCCUUGC 
siRhoC 2 Sense CCCUACUGUCUUUGAGAACUAUAUU 
siRhoC 2 Antisense AAUAUAGUUCUCAAAGACAGUAGGG 
siRhoC 3 Sense GGAUCAGUGCCUUUGGCUACCUUGA 
siRhoC 3 Antisense UCAAGGUAGCCAAAGGCACUGAUCC 
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RT-PCR 
 Total RNA was isolated from the cells using RNeasy® Plus Mini Kit columns 
(QIAGEN, Valencia, CA).  Primers targeting RhoA (sense, 5'-
CTGGTGATTGTTGGTGATGG-3'; antisense, 5'-GCGATCATAATCTTCCTGCC-3'; 
spanning 183 bp), RhoB (sense, 5'-TGCTGATCGTGTTCAGTAAG-3'; antisense, 5'-
AGCACATGAGAATGACGTCG-3'; spanning 189 bp), or RhoC (sense, 5'-
TCCTCATCGTCTTCAGCAAG-3'; antisense, 5'-GAGGATGACATCAGTGTCCG-3'; 
spanning 181 bp)  were ordered from Integrated DNA Technologies, Inc. (Coralville, IA).  
RT-PCR was performed using a QIAGEN OneStep RT-PCR Kit, as instructed by the 
manufacturer.  A QuantumRNA™ 18S Internal Standards Kit (Ambion, Austin, TX) was 
used as a standard control, as instructed by the manufacturer.  Reverse transcription was 
conducted at 50 °C for 30 min., followed by 15 min. at 95 °C, to deactivate reverse 
transcriptase.  The cDNA fragments were then denatured at 94 °C for 30 sec., annealed at 
58 °C for 1 min., and extended at 72 °C for 1 min.  After 30 cycles of amplification, 
followed by a final extension at 72 °C for 10 min., the PCR products were analyzed on a 
2% agarose gel and the bands were visualized using ethidium bromide during exposure to 
a UV transilluminator. 
Statistical analysis 
The data is expressed as the mean ± s.e.m. from the indicated number of independent 
experiments performed in triplicate. Differences were analyzed by two-factor ANOVA 
followed by a Tukey's statistical significance test. 
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CHAPTER 3 
RESULTS 
Inhibition of protein geranylgeranylation induces the sequestration of cell surface 
LPA1Rs, but not transferrin receptors, in recycling endosomes 
 We have previously shown that the clathrin- and β-arrestin-dependent 
internalization of LPA1R requires membrane cholesterol, since acute cholesterol 
extraction prevents β-arrestin association and blocks LPA1R endocytosis (Murph et al., 
2003; Urs et al., 2005).  To further study this, we examined the effects of the HMG-CoA 
reductase inhibitors atorvastatin and mevastatin on the localization of LPA1R, stably 
expressed in HeLa cells (Figure 2A).  Treatment of cells with 10 µM atorvastatin for up 
to 24 h neither altered the diffuse plasma membrane localization of LPA1R observed in 
control, vehicle-treated cells, nor did it inhibit LPA-induced internalization of LPA1R 
into endosomes (Figure 2A, 24 h 10 μM LPA).  In contrast, incubation of cells with 
atorvastatin for 48 h induced the localization of LPA1R into endosomal structures even in 
the absence of exogenously added LPA, and subsequent addition of LPA (10 μM) did not 
further enhance this endosomal localization.  Atorvastatin did not alter cell viability over 
this 48 h treatment time (data not shown).  Treatment with another HMG-CoA reductase 
inhibitor, mevastatin (10 μM), also induced an endosomal localization of LPA1R, 
indicating that this effect was not unique to atorvastatin. 
 We have previously shown that LPA1R localizes to transferrin receptor+ recycling 
endosomes following agonist stimulation (Murph et al., 2003).  Double-label 
immunofluorescence labeling experiments showed that LPA1R co-localized with both 
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transferrin receptors and co-expressed Rab11-GFP following atorvastatin-induced 
sequestration (Figure 2B).  In contrast, LPA1R showed little co-localization with the early 
endosomal marker, EEA1 (data not shown).  This suggested that statin treatment led to 
sequestration of LPA1R in juxtanuclear recycling endosomes.  To assess effects of this 
altered distribution of LPA1Rs on signaling, we examined the effects of atorvastatin (1 
μM) on the kinetics of LPA stimulation of phosphoinositide (PI) hydrolysis, which is 
mediated by Gαq and phospholipase C (Urs et al., 2005).  Whereas atorvastatin did not 
alter the EC50 of LPA-induced PI hydrolysis (EC50 = 1.939 μM, control and atorvastatin-
treated cells), it did reduce the rate and maximal extent of PI hydrolysis (Figure 2C). 
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Figure 2: Statins induce endosomal sequestration of LPA1Rs and reduce LPA 
signaling efficiency. 
(A) Atorvastatin (10 μM) and Mevastatin (10 μM) induce a redistribution of LPA1R 
receptors to punctate endosomal structures in a time-dependent manner independently of 
agonist stimulation as observed immunofluorescence microscopy.  Vehicle is 48 h 
treatment with DMSO.  Bar, 10 μm.  (B) Atorvastatin (10 μM for 48 h) induces the 
redistribution of LPA1Rs into TfnR+ and Rab11+ recycling endosomes.  Arrows indicate 
endosomes where LPA1R colocalizes with TfnR or GFP-Rab11.  The inset is a higher 
magnification of endosomal structures that are positive for both LPA1R and TfnR.  Bar, 
10 μm. (C) Pretreatment with atorvastatin (1 μM for 48 h) reduces the kinetics and extent 
of LPA-dependent phosphoinositide hydrolysis; cells were stimulated with 1 μM LPA for 
up to 60 min. Values represent the means ± s.e.m. of triplicate measurements obtained 
from a representative experiment that was repeated three times with similar results. 
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 In addition to reducing endogenous cholesterol production, statins also deplete 
isoprenoid lipids, which are involved in protein prenylation (Figure 3) (Leung et al., 
2006).  Since we have shown that acute cholesterol depletion inhibits LPA1R 
internalization (Urs et al., 2005) rather than induce internalization, we hypothesized that 
atorvastatin-induced endosomal sequestration might be due to its affects on isoprenoid 
abundance.  To test this, we compared the effects of combining atorvastatin (1 μM) with 
different isoprenoids on the localization of LPA1R (Figure 4A). We hypothesized that 
adding back the relevant downstream lipid product would prevent atorvastatin-induced 
endosomal sequestration and thus, reduce the colocalization of LPA1Rs with TfnR.   
LPA1R localized to TfnR+ endosomes in cells treated with atorvastatin alone and in cells 
treated with atorvastatin plus either farnesylpyrophosphate (FPP) (10 μM) or ubiquinone 
(50 μM); indicating that these lipid products do not rescue the atorvastatin-induced 
endosomal sequestration of LPA1Rs.   In contrast, LPA1Rs remained at the cell surface, 
like control untreated cells, when treated with atorvastatin and 
geranylgeranylpyrophosphate (GGPP) (1 μM); indicating that this lipid prevents 
atorvastatin-induced endosomal sequestration of LPA1Rs.  Quantification of the 
percentage of cells exhibiting LPA1R co-localization with TfnR (e.g., a measure of 
endosomal sequestration) indicated that co-addition of either 
geranylgeranylpyrophosphate (GGPP) (1 μM) or geranylgeraniol (GGOH) (1 μM) 
markedly reduced atorvastatin-induced endosomal sequestration of LPA1Rs; neither 
farnesylpyrophosphate (FPP) (1 μM or 10 μM) nor farnesol (FOH) (1 μM or 10 μM) was 
able to inhibit atorvastatin-induced endosomal sequestration (Figure 4B).  These results 
suggested that atorvastatin-dependent depletion of geranylgeranylpyrophosphate was 
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responsible for the endosomal sequestration of LPA1R and that defects in protein 
geranylgeranylation of some relevant target was the primary cause. 
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Figure 3: HMG-CoA reductase pathway. 
Diagram of the HMG-CoA reductase pathway leading to isoprenoid synthesis and protein 
prenylation. 
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Figure 4: Co-addition of the down-stream HMG-CoA reductase product, GGPP, 
prevents atorvastatin-induced sequestration of LPA1Rs in recycling endosomes. 
(A) Addition of GGPP (1 μM), but not FPP (10 μM) or ubiquinone (50 μM) prevents 
atorvastatin-induced endosomal sequestration of LPA1R. Bar, 10 μm.  (B) Phenotypic 
quantification shows that both GGOH and GGPP reduce the atorvastatin-induced 
redistribution of LPA1R into TfnR+ recycling endosomes.  Cells were treated with the 
indicated compounds for 48 h, fixed, and processed for immunofluorescence localization 
of LPA1Rs and TfnRs.  Values are the means ± s.e.m. of quadruplicate samples (n=100 
cells/condition) from a representative experiment that was repeated three times with 
similar results. 
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 To test this hypothesis directly, we examined the effects of specific inhibitors of 
geranylgeranyltransferase-1 (GGTI-298) (McGuire et al., 1996) and farnesyltransferase 
(FTI-277) (Lerner et al., 1995) on the localization of LPA1Rs (Figure 5A).  Treatment 
with GGTI-298 for 24 h led to a marked colocalization of LPA1Rs with transferrin 
receptors in endosomes.  This increased endosomal localization of LPA1Rs could be 
observed after only 1 h of GGTI treatment (Figure 5A, bottom panels).  In contrast, 
vehicle-treated cells and cells treated with FTI-277 showed a diffuse cell surface 
localization for LPA1R with little colocalization with transferrin receptors.  These data 
indicate that inhibition of protein geranylgeranylation either through depletion of 
isoprenoids with atorvastatin or through direct inhibition of geranylgeranyltransferase-1 
with GGTI-298 induced marked redistribution of LPA1Rs to recycling endosomes. 
 Previous studies have shown that agonist stimulation induces the internalization 
of surface LPA1Rs into endosomes (Wang et al., 2001; Murph et al., 2003; Urs et al., 
2005).  We next quantified the effects of atorvastatin, GGTI-298, and FTI-277 on the 
extent of LPA1R sequestration in recycling endosomes by using image analysis to 
measure the co-localization of LPA1Rs and transferrin receptors (Figure 5B).  As 
expected, agonist stimulation with LPA (10 μM) greatly enhanced colocalization of 
LPA1Rs and TfnRs to approximately 80% per cell.  Atorvastatin (10 μM, 48 h) and 
GGTI-298 (20 μM, 24 h) also enhanced the colocalization of LPA1Rs and TfnRs to 85% 
and 78% per cell, respectively.  In contrast, FTI-277 (20 μM, 24 h) did not promote the 
colocalization of LPA1Rs and TfnRs in recycling endosomes (only 24% fluorescence 
overlap). 
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Figure 5: Atorvastatin and GGTI induce the sequestration of LPA1Rs. 
(A) Treatment with the geranylgeranyltransferase-I inhibitor, GGTI-298, for 24 h induces 
the localization of LPA1Rs to TfnR+ endosomes (upper panel); localization of LPA1Rs to 
endosomes was observed as quickly as after 1 h of treatment with GGTI-298 (lower 
panels).  The farnesyltransferase inhibitor, FTI-277 (20 μM, 24 h), did not induce 
endosomal localization of LPA1Rs.  Bar, 10 μm.  (B) LPA, atorvastatin, and GGTI-298 
increase the colocalization of LPA1Rs and TfnRs in recycling endosomes as determined 
by immunofluorescence microscopy and quantification of fluorescence overlap between 
the two proteins.  The data are the mean ± s.e.m. of the extent of fluorescence overlap; 15 
cells per condition were analyzed and the data are from a representative experiment, 
which was repeated at least three times with similar results. 
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 To further investigate whether the LPA1Rs that accumulate in endosomes are 
internalized from the cell surface, we took advantage of the fact that the N-terminal 
epitope tag (either FLAG or HA) that is present on the LPA1Rs is able to bind and 
internalize anti-epitope antibodies added to the culture medium.  We incubated HeLa 
cells that stably expressed HA-tagged LPA1Rs (for these experiments) with anti-HA 
antibodies in the presence or absence of atorvastatin (10 μM, 48 h) and then quantified 
the proportion of bound antibodies that were internalized into cells by image analysis 
(Figure 6).  Whereas only 6 ± 0.6% of the initially bound anti-HA antibodies were 
internalized and retained in untreated cells, 89 ± 3.2% of the initially bound anti-HA 
antibodies were internalized in cells treated with atorvastatin; thus, strengthening the 
hypothesis that the LPA1Rs that are sequestered in endosomes are derived from the cell 
surface.  Similarly, incubation of cells with anti-HA antibodies and GGTI-298 (20 μM, 
24 h) led to the internalization and retention of 71 ± 3% of the initially bound anti-HA 
antibodies.  Taken together, these results strongly suggested that inhibition of protein 
geranylgeranylation by atorvastatin or GGTI-298 induces the endosomal sequestration of 
cell surface LPA1Rs. 
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Figure 6: Atorvastatin and GGTI induce the sequestration of cell surface LPA1Rs. 
Atorvastatin (10 μM, 48 h) and GGTI-298 (20 μM, 24 h) induce the endosomal retention 
of internalized anti-epitope antibodies, which were initially bound to cell surface LPA1Rs 
at 4°C.  The untreated condition was incubated at 37°C for 48 h.  Following treatment 
with the inhibitors, the remaining surface antibodies were removed with an acid wash 
prior to fixation and analysis by immunofluorescence microscopy.  The data from 
fluorescence quantification of the internalized anti-epitope antibodies are shown below 
each micrograph; the data were normalized to the fluorescence intensity of antibodies 
initially bound at 4°C (see methods for more details). 
 
 
 
 
 
4°C control Untreated Atorvastatin GGTI-298
37°C       +       Acid Wash
100% 6% ± 0.6 89% ± 3.2 71% ± 3
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 To determine whether atorvastatin induced the endosomal sequestration of other 
GPCRs, we transiently expressed HA-tagged versions of either β2-adrenergic receptors 
(β2ARs) or M2 muscarinic acetylcholine receptors (M2 mAChRs) in HeLa cells, which 
stably expressed FLAG-tagged LPA1R.  In cells treated with vehicle alone, LPA1R, 
β2ARs, and M2 mAChRs were predominantly localized at the cell surface and in the 
perinuclear region of cells (Figure 7 vehicle-treated panels); this latter compartment 
readily labeled with antibodies to the Golgi complex marker, Golgin-97, suggesting that 
these were newly synthesized receptors en route to the cell surface (data not shown).  
After treatment with atorvastatin (10 μM) for 48 h, all three receptors were co-localized 
in recycling endosomes (Figure 7).  This suggested that atorvastatin induces the 
endosomal sequestration of other GPCRs, in addition to LPA1Rs.  Both β2ARs and M2 
mAChRs undergo agonist-induced endocytosis, with β2ARs utilizing a β-arrestin and 
clathrin-dependent pathway (Urs et al., 2005). 
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Figure 7: Statin treatment induces the sequestration of multiple GPCRs in recycling 
endosomes. 
β2-ARs and M2 mAChRs are sequestered in recycling endosomes with LPA1Rs following 
atorvastatin treatment (10 μM for 48 h) as observed by immunofluorescence microscopy; 
HA-tagged β2ARs or HA-tagged M2 mAChRs were expressed in HeLa cells that stably 
expressed FLAG-tagged LPA1Rs.  Arrows indicate endosomes where LPA1R colocalizes 
with β2ARs or M2 mAChRs.  Bar, 10 μm. 
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 Whereas most GPCRs undergo conditional, agonist-stimulated internalization, 
transferrin receptors are constitutively internalized and recycled from endosomes.  We 
examined the effects of atorvastatin, GGTI-298, and FTI-277 on both the internalization 
and recycling of Alexa 546-labeled transferrin (Alexa-Tfn), using image analysis to 
quantify cell-associated Alexa-Tfn.  HeLa cells stably-expressing LPA1Rs were 
incubated with vehicle (DMSO), atorvastatin (10 μM, 48 h), GGTI-298 (20 μM, 24 h), or 
FTI-277 (20 μM, 24 h) prior to incubation with Alexa-Tfn for 30 min.  Both vehicle-
treated and atorvastatin-treated cells internalized Alexa-Tfn into small punctate endocytic 
structures as well as larger juxtanuclear endosomes (Figure 8A).  Image analysis showed 
that cells treated with vehicle, atorvastatin, GGTI-298, and FTI-277 all contained nearly 
the same amount of Alexa-Tfn (Figure 8B, white bars).  This indicated that treatment of 
cells with atorvastatin, GGTI-298, or FTI-277 did not alter transferrin receptor 
endocytosis.  To assess recycling of transferrin from endosomes, cells that were loaded 
for 30 min with Alexa-Tfn were chased with medium containing the iron chelator, 
desferroxamine, and excess unlabelled transferrin for 2 h.  Immunofluorescence images 
showed a significant reduction in cell-associated Alexa-Tfn (Figure 8A); fluorescence 
quantification (Figure 8B, black bars) indicated that approximately 60% of the 
internalized Alexa-Tfn was lost from the cells, regardless of the inhibitors used.  This 
indicated that atorvastatin, GGTI-298, and FTI-277 do not inhibit transferrin receptor 
endocytosis or recycling. 
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Figure 8: Neither atorvastatin nor incubation with prenylation inhibitors alter the 
internalization or recycling of Alexa-transferrin. 
(A) Atorvastatin treatment (10 μM for 48 h) perturbs neither the internalization of Alexa 
546-Tfn into recycling endosomes nor recycling of Alexa-Tfn during a 2 h washout.  (B) 
Fluorescence image quantification showed that none of the inhibitors (atorvastatin, 
GGTI-298, and FTI-277) inhibited Alexa-Tfn internalization during a 30 min incubation 
(Load, white bars) and had no affect on Alexa-Tfn recycling out of cells (Chase, black 
bars); cells were chased for 2 h in medium containing excess unlabeled Tfn and the iron 
chelator, desferroxamine (see methods).  Values are means ± s.e.m. of the fluorescence 
intensity, which was obtained by quantifying fluorescence intensity of 15 cells per 
condition from a representative experiment that was repeated three times with similar 
results. 
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Atorvastatin and GGTI-298 reduce the cellular abundance of RhoA-related 
GTPases but do not affect Rab11 
 A variety of small GTPases, including members of the Rho and Rab family of 
GTPases, undergo geranylgeranylation, which permits them to associate with 
membranes.  Since LPA1R accumulates in TfnR+ recycling endosomes following 
treatment with atorvastatin or GGTI-298, we hypothesized that small GTPases associated 
with this compartment are the likely targets of inhibition.  The Rab11 GTPase is known 
to localize to recycling endosomes and to regulate recycling of TfnRs (Ullrich et al., 
1996).  We tested the effects of atorvastatin and GGTI-298 on the partitioning of 
endogenous Rab11 between soluble and particulate cell fractions (Figure 9A).  In control 
cells, all of the endogenous Rab11 was associated with the particulate fraction.  Neither 
treatment with atorvastatin (10 μM) nor GGTI-298 (20 μM) disrupted the association of 
Rab11 with particulate cell fractions.  These inhibitors also did not alter the cellular 
abundance of endogenous Rab11.  This suggested that Rab11 was not the target of 
atorvastatin or GGTI-298, which leads to endosomal sequestration of LPA1Rs.  To test 
whether inhibition of Rab11 would induce endosomal sequestration, we overexpressed 
either wild type Rab11-GFP or the dominant inhibitory mutant, Rab11-GFP S34N, which 
inhibits receptor recycling (Ullrich et al., 1996).  Neither overexpression of wild type 
Rab11-GFP nor Rab11-GFP S34N induced the endosomal sequestration of LPA1R, 
which was predominantly localized to the plasma membrane (Figure 9B, left panels).  
Whereas wild type Rab11-GFP localized to large perinuclear endosomal structures, 
Rab11-GFP S34N showed a diffuse cytoplasmic localization (Figure 9B, right panels).  
 54
These results suggested that atorvastatin and GGTI-298 induced endosomal sequestration 
of LPA1R is most likely not due to inhibition of Rab11 function. 
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Figure 9: Atorvastatin and GGTI-298 do not reduce the cellular abundance of 
endogenous Rab 11. 
(A) Atorvastatin and GGTI-298 do not perturb the partitioning of endogenous Rab11 
between soluble and particulate fractions and do not alter the abundance of Rab11.  HeLa 
cells expressing FLAG-LPA1R were treated with atorvastatin (10μM for 48 h) or GGTI-
298 (20 μM for 24 h) and then separated into soluble (S) or particulate (P) fractions prior 
to western blotting for endogenous Rab11. The numbers below the gels indicate the 
combined band intensities of the (S+P) fractions for each treatment, which were 
normalized to the control, vehicle-treated samples.  (B) Neither overexpression of wild 
type Rab11-GFP nor dominant inhibitory Rab 11 S34N-GFP induces endosomal 
sequestration of LPA1R.  Note that whereas wild type Rab 11-GFP associates with large 
endosomal structures, dominant inhibitory Rab 11 S34N-GFP remains in a diffuse 
cytoplasmic pattern. 
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 Whereas Rab GTPases are prenylated by Rab geranylgeranyltransferase (Pereira-
Leal et al., 2001), which is not inhibited by GGTI-298, Rho GTPases are prenylated by 
geranylgeranyltransferase-I (Denoyelle et al., 2001; Muck et al., 2004), which is 
inhibited by GGTI-298.  Indeed, most of the anti-cancer effects of statins and GGTIs are 
due to inhibition of RhoA-related GTPases (e.g., RhoA, B, or C) (Kusama et al., 2001).  
Given the high sequence identity between RhoA, B, and C (~85%), isoform-specific 
antibodies are not available.  Therefore, we transfected HeLa cells with HA-tagged forms 
of RhoA, B, or C and examined the effects of atorvastatin and GGTI-298 on the 
distribution of these tagged GTPases between soluble and particulate fractions (Figure 
10).  In control cells, both HA-RhoA and HA-RhoC were approximately equally 
distributed between soluble and particulate fractions, whereas HA-RhoB was 
predominantly localized to the particulate fraction.  Although neither atorvastatin nor 
GGTI-298 induced a noticeable shift in the distribution of HA-Rho proteins, these 
inhibitors markedly reduced the total abundance of HA-RhoC (>70% reduction) and HA-
RhoA (>60% reduction).  These inhibitors also reduced the abundance of HA-RhoB (40-
55%), but to a lesser degree than HA-RhoC and HA-RhoA. 
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Figure 10: Atorvastatin and GGTI-298 reduce the cellular abundance of HA-RhoA, 
HA-RhoB, and HA-RhoC. 
Atorvastatin and GGTI-298 greatly reduce the cellular abundance of RhoA, B, and C in 
following rank order: RhoC > RhoA >> RhoB. Cells expressing HA-tagged RhoA, B, or 
C were treated with atorvastatin (10μM for 48 h) or GGTI-298 (20 μM for 24 h) and then 
separated into soluble (S) or particulate (P) fractions prior to western blotting.  The 
numbers below the gels indicate the combined band intensities of the (S+P) fractions for 
each treatment, which were normalized to the control, vehicle-treated samples. 
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Knockdown of RhoC and RhoA induces the endosomal sequestration of LPA1Rs but 
does not affect transferrin receptor trafficking 
 To determine whether RhoA-related GTPases were involved in the endosomal 
trafficking of LPA1Rs, we transiently transfected LPA1R-expressing HeLa cells with a 
plasmid that encoded C3 transferase; an exoenzyme derived from Clostridium botulinum 
that selectively ADP-ribosylates and inactivates RhoA, B, and C (Paterson et al., 1990; 
Aktories and Just, 2005).  LPA1Rs localized to the plasma membrane in cells transfected 
with a non-specific plasmid, pBluescript, and filamentous actin (F-actin) in these cells 
was distributed in thin stress fibers and in a band that encircled the cell at the plasma 
membrane (Figure 11, pBluescript).  In cells treated with 10 μM atorvastatin for 48 h, 
LPA1Rs were sequestered in endosomes and rhodamine-phalloidin staining of stress fiber 
was reduced (Figure 11, 10 μM Atorvastatin).  In cells expressing C3 transferase, 
LPA1Rs were predominantly localized to transferrin-positive endosomes and actin stress 
fibers were greatly disrupted, indicating that Rho activity was inhibited (Ridley and Hall, 
1992).  Rhodamine-phalloidin labeled randomly localized punctate spots in the cytoplasm 
of these cells rather than the thin F-actin filaments observed in control cells.  These data 
support the hypothesis that RhoA-related GTPases regulate the trafficking of LPA1Rs 
through recycling endosomes. 
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Figure 11: C3 transferase induces the endosomal localization of LPA1Rs. 
Transient transfection of plasmid encoding Clostridium botulinum C3 transferase induces 
the localization of LPA1Rs to endosomes, similar to 10 μM atorvastatin, and disrupts the 
actin cytoskeleton as observed by immunofluorescence localization of LPA1Rs and 
rhodamine phalloidin staining of F-actin.  Bar, 10 μm. 
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 To directly test whether inhibition of RhoA-related GTPases would induce 
endosomal sequestration of LPA1R, we used specific siRNAs to knockdown expression 
of RhoA, B, or C (Figure 12).  Since antibodies specific for the individual RhoA-related 
proteins were not available, we used reverse transcriptase PCR to assess the effects of 
siRNA treatment on the mRNAs for RhoA, B, and C.  In cells transfected with control 
siRNA, specific DNA fragments for the individual RhoA-related proteins were readily 
amplified (Figure 12C, control lanes).  In contrast, DNA products were not amplified 
from cells treated with siRNAs specific for the individual RhoA isoforms (Figure 12C, 
siRNA lanes).  Endosomal sequestration was assessed by comparing the localization of 
LPA1R to TfnR (Figure 12A).  Cells treated with siRNAs specific for RhoA and RhoC 
showed extensive co-localization of LPA1R and TfnR, whereas cells treated with siRNA 
for RhoB showed little co-localization of LPA1R and TfnR; control siRNA-treated cells 
showed no co-localization of LPA1R and TfnR.  This suggested that knockdown of either 
RhoA or RhoC increased the localization of LPA1R to recycling endosomes. 
 To quantify this effect, we determined both the number of cells displaying co-
localization of LPA1R and TfnR, in random fields of cells, and the extent of fluorescence 
pixel overlap between LPA1R-specific staining and TfnR-specific staining in individual 
cells (Figure 12B).  In cells treated with control siRNAs, the percentage of cells 
displaying co-localization of LPA1R and TfnRs were approximately 10% and the average 
fluorescence pixel overlap in individual cells was about 25%.  In contrast, approximately 
95% of cells treated with atorvastatin (10 μM) for 48 h displayed co-localization of 
LPA1R and TfnR.  An average fluorescence pixel overlap of about 80% was observed 
between LPA1R and TfnR labeling in individual cells.  Remarkably, approximately 80% 
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of cells treated with siRNA for RhoC showed co-localization of LPA1R and TfnR, and 
about 80% pixel overlap between the two proteins was observed in individual cells.  
Approximately 70% of cells treated with siRNA for RhoA showed co-localization for 
LPA1R and TfnR and a little more than 60% fluorescence pixel overlap.  Cells treated 
with siRNA for RhoB displayed co-localization of LPA1R and TfnR in about 35% of 
cells and about 50% fluorescence pixel overlap.  These results indicate that siRhoC was 
the most potent inducer of endosomal sequestration of LPA1R, whereas siRhoA was 
slightly less potent than siRhoC at inducing endosomal sequestration.  SiRhoB was not 
nearly as potent as either siRhoC or siRhoA in inducing endosomal sequestration of 
LPA1R.  Given that RhoB has been implicated in trafficking from early endosomes to 
lysosomes (Mellor et al., 1998; Gampel et al., 1999; Fernandez-Borja et al., 2005), it is 
probable that perturbing RhoB function has indirect effects on trafficking through 
recycling endosomes.  Finally, we tested the effects of siRhoA, siRhoB, and siRhoC on 
the endocytosis and recycling of Alexa594-Tfn (Figure 13).  In contrast to the 
sequestration of LPA1Rs observed in siRhoA- and siRhoC-treated cells, neither Alexa-
Tfn internalization (Load) nor recycling (Chase) was altered by siRNA-mediated 
reduction of these two GTPases.  Taken together, these results suggest that RhoA and 
RhoC are critical for LPA1R trafficking through recycling endosomes but not for 
transferrin receptor trafficking. 
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Figure 12: Depletion of cellular RhoA or RhoC induces endosomal sequestration of 
LPA1R. 
(A) SiRNA knockdown of RhoA or RhoC induces the endosomal co-localization of 
LPA1R and TfnRs.  Knockdown of RhoB partially induces the localization of LPA1R to 
Tfn+ recycling endosomes.  (B) SiRNA reduction of RhoA, B, and C increases the 
sequestration of LPA1R in TfnR+ recycling endosomes.  Endosomal sequestration was 
quantified by phenotypic counting (100 cells/condition) and by measurement of 
fluorescence pixel overlap (9 cells/condition).  The values are the means ± s.e.m. from a 
representative experiment that was repeated three times with similar results.  (C) RT-
PCR analysis shows that specific siRNA treatment eliminates the expression of RhoA, 
RhoB, and RhoC mRNA. 
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Figure 13: Depletion of RhoA, RhoB, or RhoC does not affect transferrin recycling. 
SiRNA reduction of RhoA, B, or C did not affect the internalization or recycling of 
Alexa-Tfn.  Cells were incubated with Alexa-Tfn (20 μg/ml, 30 min, “Load”, white bars), 
rinsed and either fixed or incubated in medium containing excess unlabeled transferrin 
and the iron chelator, desferroxamine, for 2 hr (Chase, black bars) prior to fixation.  The 
fluorescence intensity of cell-associated Alexa-Tfn was quantified from 15 cells per 
condition from a representative experiment. 
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CHAPTER 4 
DISCUSSION 
 
 We have shown that atorvastatin, mevastatin, GGTI-298, and siRNA knockdown 
of RhoC and RhoA lead to a novel endosomal sequestration of cell surface LPA1R 
receptors.  The most likely cause for the sequestration of LPA1Rs, as well as β2ARs and 
M2 mAChRs, in endosomes, is through inhibition of receptor recycling, which leads to 
the trapping of receptors that are internalized during basal endocytosis, in recycling 
endosomes.  Atorvastatin, mevastatin, and GGTI-298 lead to defects in protein 
geranylgeranylation, either by depletion of geranylgeranylpyrophosphate, which is 
required for protein geranylgeranylation, or by direct inhibition of 
geranylgeranyltransferase-I, respectively.  RhoA and RhoC are both prenylated by 
geranylgeranyltransferase-I (Braun et al., 1989; Chardin et al., 1989; Aktories et al., 
2004).  Taken together, we hypothesize that atorvastatin and GGTI-298 induce 
endosomal sequestration by preventing the geranylgeranylation of RhoC and RhoA, 
which inhibits their function and leads to the inhibition of receptor recycling. 
 Statins are the most widely prescribed class of prescription drugs in the world and 
have traditionally been used to lower blood cholesterol in patients.  The peak plasma 
concentration of atorvastatin prescribed for cholesterol reduction in patients ranges from 
0.02 to 0.05 μM (Corsini et al., 1999).   The lowest concentration of atorvastatin, which 
induces endosomal sequestration of LPA1Rs, is 0.1 μM (unpublished observations; P.D.S 
and H.R.).  This is at least a 5-fold higher concentration of atorvastatin than is used for 
therapeutic reduction of cholesterol in patients.  The major side effects of high dose statin 
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treatment are myopathy and rhabdomyolysis, typically in striated muscle (Kusama et al., 
2001).  Given that 10- to 100-fold higher concentrations of atorvastatin were required to 
observe GPCR sequestration, in vitro, we do not expect that plasma concentrations of 
atorvastatin in patients approach levels where this type of receptor sequestration occurs in 
vivo, with the caveat that localized increases in atorvastatin concentration may occur in 
certain areas of the body.  Rather, our data indicate that atorvastatin at these higher 
concentrations is a very useful experimental tool to investigate endosomal recycling in 
vitro. 
 Inhibition of HMG-CoA reductase depletes the downstream products of the 
mevalonate pathway, which include not only sterols but also retinoids, ubiquinone, 
dolichols, and the isoprenoids, farnesylpyrophosphate and geranylgeranylpyrophosphate 
(Chan et al., 2003).  The latter products are utilized for protein prenylation.  Recently, 
statins have gained wide interest as anti-cancer agents and have been shown to inhibit the 
growth and migration of a broad range of cancer cells in vitro, including those from 
breast cancer (Denoyelle et al., 2001), lymphoma (Matar et al., 1999), and glioblastoma 
(Kikuchi et al., 1997). 
 Many Rho GTPases have been implicated in the regulation of membrane 
trafficking (Symons and Rusk, 2003).  RhoA, Rac, and Cdc42 have been implicated in 
endocytosis from the plasma membrane, whereas RhoB and RhoD are involved in 
endosomal trafficking.  RhoD regulates the distribution and motility of early endosomes 
(Murphy et al., 1996; Murphy et al., 2001).  Constitutively active mutants of RhoA and 
Rac1 are potent inhibitors of transferrin receptor endocytosis (Lamaze et al., 1996).  The 
downstream Rac effector, synaptojanin2, is involved in Rac1 regulation of transferrin 
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receptor endocytosis (Malecz et al., 2000).  RhoB has been shown to regulate the 
trafficking of EGF receptors from early endosomes to lysosomes through effects on F-
actin assembly (Gampel et al., 1999; Fernandez-Borja et al., 2005).  The Cdc42 effector, 
ACK1 kinase, also interacts with clathrin heavy chain and can influence transferrin 
receptor endocytosis (Teo et al., 2001). 
 In this study, we observed that siRNA-mediated reduction of RhoC or, to a lesser 
degree, RhoA led to sequestration of LPA1R in recycling endosomes (Figure 12). These 
observations were further strengthened by the finding that transient transfection of C3 
transferase, which inhibits RhoA-related proteins, also induced a sequestration of 
LPA1Rs in recycling endosomes (Figure 11).  In contrast, neither dominant inhibitory 
mutants of Rac1 (T17N) nor Cdc42 (T17N) induced endosomal sequestration of LPA1R 
(P.D.S. and H.R., unpublished observations).  The finding that reduction of either RhoA 
or RhoC induced endosomal sequestration of LPA1R suggests a functional overlap 
between these proteins (Figure 12).  It is interesting to note that RhoA and RhoC 
cooperate to promote proliferation and invasiveness, respectively, of esophageal 
squamous cell carcinoma cells and certain breast cancer cell lines (Pille et al., 2005; 
Faried et al., 2006).  The identification of RhoC as an important regulator of endosomal 
trafficking raises the novel possibility that this RhoC function is also important for the 
stimulation of cancer cell invasion.  RhoC is overexpressed in a variety of metastatic and 
invasive cancers including: breast (Pille et al., 2005), ovarian (Horiuchi et al., 2003), and 
pancreatic ductal cancers (Suwa et al., 1998), as well as melanoma (Collisson et al., 
2003; Ruth et al., 2006); however, its precise role in stimulating cancer cell invasion is 
not clear. 
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 The mechanisms by which RhoC and RhoA regulate GPCR trafficking through 
recycling endosomes are not clear. Another RhoA-related GTPase, RhoB, has been 
shown to regulate the trafficking of EGF receptors from early endosomes to lysosomes 
by mediating the assembly of F-actin around endosomes, via the formin protein, mDia1 
(Fernandez-Borja et al., 2005), and through the action of the protein kinase, PRK1 
(Mellor et al., 1998).  The exact role of PRK1 in endosomal trafficking is unknown.  
RhoB- and Dia1-mediated actin assembly on endosomal structures is thought to link 
endosomes to F-actin fibers and perhaps coordinate endosome motility (Fernandez-Borja 
et al., 2005).  RhoA, B, and C share about 85% amino acid identity and interact with 
most of the same effector proteins.  Thus, it is possible that RhoC and RhoA utilize a 
similar mechanism and/or effectors in the regulation of recycling endosomal trafficking 
as RhoB. 
 An important distinction to note is that while atorvastatin and knockdown of 
RhoA and RhoC perturbed the trafficking of GPCRs (e.g., induced endosomal 
sequestration), these treatments did not perturb the internalization or recycling of Alexa-
transferrin (Figures 8 and 13).  This suggests that GPCR trafficking through recycling 
endosomes is perhaps regulated differently from transferrin receptors.  Indeed, dominant 
inhibitory Rab11 S34N can inhibit the recycling of transferrin receptors (Ullrich et al., 
1996), but does not induce endosomal sequestration of LPA1R receptors (Figure 9B).  
Mechanistic details about trafficking through recycling endosomes are beginning to 
emerge.  In addition to the Rab11 GTPase, RME-1 and its human homologue, EHD1, 
localize to recycling endosomes and are important regulators of endocytic recycling (Lin 
et al., 2001). The RME-1 protein was identified in a genetic screen in C. elegans for 
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endocytosis mutants, and dominant negative RME-1/EHD1 slowed TfnR recycling and 
altered the cellular distribution of recycling endosomes (Grant et al., 2001).  Rabenosyn-
5, a Rab4/Rab5 effector, physically interacts with EHD1 and is thought to act 
sequentially with EHD1 in mediating trafficking from early endosomes to recycling 
endosomes and subsequently to the plasma membrane (Naslavsky et al., 2004a). 
 In conclusion, we have described a process whereby inhibition of protein 
geranylgeranylation, with atorvastatin or GGTI-298, leads to a novel sequestration of 
multiple GPCRs in recycling endosomes.  We speculate that the defective prenylation of 
the RhoA-related GTPases, RhoC and RhoA, is the cause of statin- and GGTI-mediated 
endosomal sequestration since siRNA knockdown of either of these two GTPases also 
causes GPCR sequestration in recycling endosomes.  Interestingly, none of these 
perturbations altered transferrin receptor internalization and recycling, which suggests 
that different mechanisms of regulation are involved in the trafficking of GPCRs and 
transferrin receptors from recycling endosomes.  Future studies are expected to reveal not 
only the role of RhoC and RhoA in endocytic recycling but also the relationship between 
Rab11-regulated and Rho-regulated recycling. 
 
CHAPTERS 
FUTURE DIRECTIONS 
We have shown that RhoA, B, and e play a role in the endocytic trafficking of 
LPA1Rs. In the results described above, we have not monitored the prenylation state of 
RhoA, B, and e in response to statin and GGTI treatment. Thus, a potential future study 
would be to quantitatively determine the levels of endogenous RhoA, B, and e present, 
and their level of prenylation, in control, statin, and GGTI treated cells. It is important to 
note that prenylation of RhoB is achieved by attaching a geranylgeranyl group that is 20 
carbons in length or a famesyl group that is 15 carbons in length. In contrast, prenylation 
of Rhoe and A is achieved by attachment of a geranylgeranyl group (Adamson et al., 
I 992). To test this, we would measure the level of geranylgeranylation of RhoA, B, and 
e, and also measure the level of famesylation of RhoB. The expected result of GGTI 
treatment would be a decrease in the pool of geranylgeranylated-RhoB, and an increase in 
the pool of famesylated-RhoB. These studies will more closely link the trafficking 
effects that we have observed, in response to statin and GGTI treatment, with direct 
impacts on RhoA, B, and C. 
Since we have identified Rhoe and A as participants m the regulation of 
endocytic recycling, the next step will be to identify the specific effector proteins that 
regulate endocytic trafficking. Immunofluorescence labeling could be utilized in initial 
experiments to examine the localization of possible effectors in both control cells and 
cells that have been treated with statin or GGTI. If we observe effectors that localize to 
endosomes in control cells, but lose the endosomal localization with statin or GGTI 
treatment, it would indicate that these effectors are possibly recruited to endosomes by 
Errata - p. 17 
active, prenylated Rhoe or A. One method to determine which effectors may be 
modulating trafficking would be to overexpress inactive mutant forms of potential 
effectors and examine their effects on trafficking. Further studies could utilize siRNA 
directed against specific effectors to help determine their functions in endocytic 
trafficking of LP A 1 receptors. The results of these studies will help us form a better 
model of the mechanisms that drive endocytic trafficking ofLPA1 receptors. 
One interesting possibility is that Rhoe and A are functionally equivalent. There 
is evidence that the gene encoding Rhoe resulted from an incomplete duplication of the 
gene encoding RhoA (Karnoub et al., 2004 ). However, it is also possible that both Rhoe 
and A are required for recycling of LPA 1Rs to the cell surface, possibly by recruiting 
slightly different pools of effectors. Our results have shown that siRNA knockdown of 
either Rhoe or A results in the sequestration of LPA 1Rs. If Rhoe and A were perfectly 
functionally interchangeable, it would be reasonable to expect that one would compensate 
for the other and we would not see sequestration resulting from knockdown of either 
protein individually. A possible explanation is that Rhoe and A function at two different, 
but closely related steps. One possible mechanism is that one of the two Rho proteins 
(Rhoe or A) could be involved with sorting the receptors into developing vesicles, while 
the other Rho protein (Rhoe or A) may be involved with the recruitment of coat proteins 
that will pinch the vesicle off from the compartment. Another possibility is that a Rho 
protein mediates the interaction of transport vesicles with a motor protein that carries the 
vesicles along the cytoskeleton. One potential study to examine these possibilities would 
be to visualize the localization of LPA 1Rs in fine detail using immunogold electron 
microscopy (EM), in response to siRhoA, siRhoB, and siRhoe, both individually and in 
Errata - p. 18 
combination. The results of this study would help to place RhoA, B, and C at potentially 
distinct points in the trafficking pathway of LP A 1 Rs. 
Overall, we have identified a novel role for RhoC and A in the endocytic 
recycling of GPCRs. This is the first demonstration, of which we are aware, of a role for 
Rho proteins in endocytic recycling and will hopefully lead to future developments in the 
understanding of the dynamic processes by which receptors are returned to the cell 
surface. 
Errata - p. 19 
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APPENDIX A 
PROTOCOLS 
 
Splitting mammalian cells 
1. Aspirate media and add 2 mL trypsin and incubate for 2-3 minutes at 37 °C. 
2. Add 4 mL complete media to cells and pipet cells 20 times to get uniform suspension. 
3. Add 0.4-1.0 mL suspended cells to 10 cm dish containing 10 mL of complete media. 
4. Label dish with date, split number, cell line, dilution, and initials. 
5. If using cells for experimental purposes, count number of cells using hemacytometer. 
 
Plating mammalian cells 
1. Flame ethanol soaked coverslips and let air dry for a few seconds before adding to 10 
cm dish or 6-well plate. 
2. After counting number of cells, place appropriate amount of cells into a conical tube 
containing media and mix well. 
3. Dispense 2 mL or 6 mL of cells into 6-well plate or 10 cm dish, respectively. 
 
Freezing back stocks of mammalian cells 
1. Wipe the work area, bottle tops, and gloves very well with ethanol. 
2. Aspirate media from cell dish or flask. 
3. Rinse cells with enough trypsin to just cover the bottom of the flask. 
4. Aspirate off trypsin to remove residual media. 
5. Cover flask trypsin and incubate in CO2 chamber for 2-3 minutes. 
6. Add complete media to flask (approx. 2 times the amount of trypsin used) to 
neutralize trypsin. 
7. Label cryogenic tubes with cell line name, date, and your initials. 
8. Place cells into chilled 50 mL Corning tube. 
9. Centrifuge cells at 1200rpm, 4 °C for 5 min. 
10. Aspirate off media with sterile pastuer pipet. 
11. Resuspend pellet in 5 ml freezing media (10% DMSO, 90% Fetal Bovine). 
12. Aliquot 1 ml of cells into cryogenic tubes VERY CAREFULLY!!! 
13. Place in Styrofoam container and place into -80 °C for 3 days. 
14. Move tubes to liquid nitrogen for storage. 
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ExGen 500 transfection 
Considerations:  
1. 1. High quality DNA of 1.8 OD ratio or higher is recommended.  
2. 2. Recommended cell density is around 50% at time of transfection.  
3. 3. Optimal detection of transfection can be determined by a reporter gene.  
4. 4. Transfection efficiency is higher in the presence of serum without antibiotics.  
 
Day 1: Seed 0.45x 106 HeLa cells (density depends on cell type) in a 10 cm dish 
containing complete DMEM (-antibiotics).  
Day 2: Transfect in the morning. Prior to transfection, transfer coverslips to a 6-well plate 
containing 2 mL of complete DMEM (-antibiotics).  
Day 3: Change the media.  
Day 4: Perform the assay.  
Day 2: Procedure for 6-well plate: Use 1 μg  to 3.3 μl ratio of DNA to Ex-Gen.  
1. Dilute recommended amount of DNA (Total 2.0 μg/6-well) into 200 μl of 150 mM 
NaCl.  
2. Vortex briefly and spin down.  
3. Add 7.0 μl of ExGen500 to DNA solution and immediately vortex for 10 sec.  
4. Incubate at room temperature for 10 min.  
5. Add the ExGen500/DNA mixture to one well of 6-well plate and place on shaker for 
5 min.  
6. Incubate for 24 h and change media following day.  
7. Assay 48 h after transfection. 
 
Internalization of Alexa-labeled human transferrin 
1. Plate cells on 12 nm circle (No. 1) coverslips and grow until experiment in complete 
culture medium (containing FBS, antibiotics, etc.). 
2. Transfer individual coverslips to wells in 12 well dish. 
3. Rinse cells 3x with serum-free medium containing 0.5% BSA (BSA/SFM). 
4. Incubate cells in BSA/SFM for 30 min at 37 °C. (This step chases out the native 
transferring bound to the endogenous receptors.)  Add any drug treatments at this 
time as well. 
5. Add 10μl of a 50mg stock of Alexa-Labeled Transferrin (in molecular probes box 
stored at 4°C). 
6. Incubate cells at 37 °C for 20min. 
7. Rinse cells briefly with 0.5% acetic acid, 0.5 M NaCl, and then several times with 
complete medium (containing serum). 
8. Fix for 10 min with 2% formaldehyde in PBS. 
9. Rinse for 5 min with 1X PBS. 
10.  Mount coverslips on slide. 
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Indirect immunofluorescence 
1. Day 1: Plate 0.10 x 106 HeLa, 0.13 x 106 MEF wt, 0.08 x 106 MEF KO 1/2 cells on 
flamed 12 mm circle glass coverslips in a 6-well dish. 
2. Day 2: Begin transfection protocol according to manufacturer’s protocol. 
3. Day 3: Treat as required for experimental protocol. 
4. Transfer coverslips to a 12-well dish containing 1 mL of chilled 2% formaldehyde in 
PBS pH 7.4 
5. Incubate for 10 minutes at room temperature. 
6. Remove fixative and add 1 mL of 10% adult calf serm and 0.02% sodium azide in 
PBS (PBS/serum). 
7. Incubate for 5 minutes at room temperature. 
8. Dilute primary antibodies into PBS/serum containing 0.2% saponin and spin for 5 
minutes at 14,000 rpm. 
9. Add parafilm to the bottom of a 150 mm Petri dish and label for each corresponding 
coverslip in the 12-well plate. 
10. Add 25 µl of the diluted antibody solution to appropriate spot on the parafilm. 
11. Using forceps pick up individual coverslips, wick off excess fluid on paper towel, and 
add cell side down directly onto 25 µl of diluted antibody. 
12. Place cover on 150 mm Petri dish and incubate for 45 minutes. 
13. Carefully transfer coverslip, cell-side up, back into 12-well dish containing 
PBS/serum. 
14. Wash cells with 1 mL PBS/serum (3 x for 5 minutes) 
15. Dilute fluorescently-labeled secondary antibodies in PBS/serum + 0.2% saponin and 
spin for 5 minutes at 14,000 rpm. 
16. Invert coverslips onto 25 µl of diluted secondary on parafilm as described above. 
17. Incubate for 45 minutes. 
18. Wash coverslips 3 x 5 minutes with PBS/serum. 
19. Rinse coverslips with 1X PBS and mount onto glass slides with fluoromount G. 
20. Seal edges of coverslips with clear nail polish. 
 
Metamorph colocalization 
1. Open and load image of interest 
 Deconvolute images prior to quantitation 
2. Process Menu 
 Select “2D deconvolution” 
 Click nearest neighbor and Apply (adjust if needed) 
 Display color combine 
3. Display Menu 
 Select “Color Separate” 
 Click red, green or blue ---“new” 
4. Select rectangle box in Regions tools and place in Blank region of image 
5. Regions Menu 
 Select “Transfer Region” to place blank in all colors of image 
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6. Measure Menu 
 Select “Show Region Statistics” 
 *the “Use Threshold” box should NOT be checked 
 *region around box should be blinking (active) 
 *Add the sum of average and standard deviation computed for each color image. 
 Record measurements for each color. 
7. Measure Menu 
 Select “Threshold Image” 
 *Make sure State is Off 
 Insert the values derived from previous step into the “Low Intensity” box 
8. Region Tools 
 Select line or box tool to mark the areas of image to analyze. Double click to 
 activate. 
9. Regions Menu 
 With image outline blinking, select Transfer Region 
 Transfer outline of interest to all the color images separated earlier 
10. Measure Menu 
 Select “Show Region Statistics” 
 *Check the “inclusive” box for each color of the image 
 * Add the sum of the average and standard deviation computed 
11. Measure Menu 
 Select “Threshold Image” 
 *input the sum calculated above into the “Low intensity” box 
12. Applications Menu 
 Select “Measure colocalization” 
 *set image to “A” or “B” as appropriate 
 *check the “show percentage box” 
 *log into Excel spreadsheet 
 
Fractionation of total membranes and cytosol 
1. Rinse cells twice with ice-cold PBS on ice/H2O bath.   
2. Add 4 ml cold PBS and scrape cells, add to a cold 15 ml screw-cap tube.  Rinse cells 
with 2 ml PBS and add to tube. 
3. Pellet cells (1200 rpm, 5 min in Sorvall RT6000D table top = 300 x g). 
4. Resuspend cells in 2 ml of (250 mM sucrose, 10mM Tris-Cl pH 7.4). 
5. Pellet cells as described in step 3. 
6. Resuspend cells in ~ 500 μl of (100 mM sucrose, 10 mM Tris-Cl pH 7.4).  [You 
should vary the volume you resuspend the cells in depending on how many cells you 
have (e.g., resuspend in less (~ 200 μl) if you have fewer cells).] 
7. Transfer suspension to a small petri dish on ice. 
8. Break cells by passing suspension through 25 guage syringe needle attached to a 1 ml 
syringe (up/down 5-10 times for HeLa cells, 10-15 for Cos or NRK cells).  Examine 
under scope to check for breakage. 
9. Transfer to chilled microfuge tube, centrifuge in Biofuge at 4°C (speed 3.5, 5 min). 
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10. Transfer the postnuclear supernatant (PNS) to chilled microfuge tube.  At this point, 
you can split PNS into aliquots (120 μl) for various treatments or manipulations.  
Remember to always save some of PNS for gel. 
11. Transfer 120 μl aliquots of PNS to ultracentrifuge tubes (Beckman Polyallomer 
tubes). 
12. Centrifuge in a TLA 100.2 rotor in table top ultracentrifuge at 60,000 rpm ~ 150,000 
x g (30 min, 4°C.) 
13. Remove supe (cytosol, 120 μl) and add 40 μl of 4x SDS sample buffer. 
14. Solubilize pellet (total membranes) in 160 μl 1x SDS sample buffer. 
15. Boil samples 3 min at 95 °C. 
16. Separate by electrophoresis (use 13% gels for small GTPases). 
 
Solutions     20 ml 
250 mM sucrose    5 ml of 1 M stock 
10 mM Tris-Cl pH 7.4   0.2 ml of 1 M stock ? add dH2O to 20 ml 
final 
 
100 mM sucrose    2 ml of 1 M stock 
10 mM Tris-Cl pH 7.4   0.2 ml of 1 M stock ? add dH2O to 20 ml 
final 
 
Cell lysis for Western blotting 
1. Rinse culture dishes of cells twice with ice-cold 1X PBS 
2. Scrape cells into a pool at the bottom of the dish using 1X PBS with protease and 
phosphatase inhibitors added fresh each time 
3. Transfer pool of cells into an ice-cold microfuge tube and spin in a cold centrifuge at 
500-1200 rpm for about 5-15 min. 
4. Add 200-500 μl (HeLa) of lysis buffer to the cell pellet after removing the 
supernatant. 
 Lysis Buffer: 
 1% NP-40 1mL 
 1% deoxycholate salt 1g 
 0.15M NaCl (from 5M stock) 3mL 
 0.1% SDS (from 20% stock) 0.5mL 
 0.01M sodium phosphate 7.2 10mL 
 2mM EDTA (from 0.5M stock) 400μl 
 50mM NaF (from 1M stock) 5mL 
 0.2M orthovanadate (from 0.1M stock) 2mL 
 H2O (to 100mL total volume) 78mL 
 *Add fresh protease inhibitors each time 
5. Allow the cells to lyse on ice for 30 min with vortexing every 10 min. 
6. Spin in the cold centrifuge for 15 min, remove supernatant for BCA Assay. 
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SDS-PAGE gel recipe 
MINIGEL: SEPARATING GEL (10 mL) 
Reagent:    7%  10% 
40% Acrylamide   1.75 mL 2.5 mL 
1.5M Tris, 0.4% SDS pH 8.8   2.5 mL  2.5 mL 
ddH2O     5.25 mL 5.0 mL 
10% APS *fresh   50 µl  50 µl 
TEMED    10 µl  10 µl 
 
MINIGEL: STACKING GEL (5 mL) 
Reagent: 
40% Acrylamide   0.375 mL 
0.5M Tris, 0.4% SDS pH 6.8   1.25 mL 
ddH2O     3.375 mL 
10% APS *fresh   50 µl 
TEMED    7.5 µl 
 
SDS-PAGE setup 
1. Assemble two glass plates using green casting stand from Bio-Rad. 
2. Place cast upright in the Bio-Rad assembly stand to seal bottom of gel. 
3. Pour mixed separating gel using a Pasteur pipet ensuring no air bubbles form. 
4. Overlay gel with isopropanol to ensure a flat surface and to exclude air.   
5. Allow ~45 minutes for gel to polymerize. 
6. Pour stacking gel onto top of set separating gel and insert comb.   
7. Allow gel to set.  May store gel overnight at 40C. 
8. Place one or two gels into the slots of the Mini Tran Blot Cell, ensuring that the short 
plate faces the interior of the cell.   
9. Remove comb and remove bubbles from wells using a syringe. 
10. Load 5 µl of protein standard and ~20 µl of protein sample to corresponding wells. 
11. Fill the middle buffer chamber with 1X SDS running buffer (196 mM glycine, 50 
mM Tris-Cl pH 8.3, 0.1% SDS).  Once running buffer reaches lanes slowly add rest 
of running buffer and ensure that samples do not run over into adjacent lanes.  Fill to 
top.  
12. Fill the lower buffer chamber with 1X SDS running buffer until it covers the wire 
found on the inside of the gel apparatus. 
13. Connect the electrode cables to power supply. 
14. Run gel at 150V for ~1 hour or until dye runs off gel. 
 
Western Blotting with chemiluminescence detection 
1. Following SDS-PAGE, carefully separate glass plates and float the gel off the glass 
plate under chilled transfer buffer.   
2. Assemble sandwich in this order on top of black side of sandwich. 
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a. Scotch-brite pad (presoaked in transfer buffer) 
b. Whatman filter paper (presoaked in transfer buffer) 
c. SDS-PAGE Gel 
d. Nitrocellulose paper (presoaked in transfer buffer) 
i. Roll out air bubbles  
e. Whatman filter paper (presoaked in transfer buffer) 
f. Scotch-brite pad 
3. Seal cassette, place in Mini Protean II Cell, fill with chilled transfer buffer, and add 
ice pack. 
4. Connect the electrode cables to power supply. 
5. Run gel at 50V for 1.5 hours or until loading dye just runs off of bottom of gel. 
6. Transfer nitrocellulose to blocking buffer (Tris buffered saline with 0.1% Tween 20 
(0.1% TBST) and 2% milk) 
7. Block nitrocellulose for 2 hours at room temperature on rocking platform. 
8. Transfer nitrocellulose to ziplock bag containing diluted primary antibody in 10 mL 
of blocking buffer. 
9. Incubate on rocker overnight at 4 °C.    
10. Wash nitrocellulose 2Xs with 0.1% TBST. 
11. Incubate with secondary antibody diluted in blocking buffer for 1 hour on rocker at 
room temperature.  (HRP conjugated donkey 1:5000) 
12. Wash nitrocellulose 3Xs with 0.1% TBST. 
13. Treat on plastic wrap with West Pico solution (1:1 mixture of Solution A and 
Solution B; made up just before use) for 5 minutes. 
14. Transfer nitrocellulose to plastic wrap and place in film cassette and go to dark room. 
15. Expose film for 1 minute and increase or decrease exposure time as needed. 
16. Develop film using the automated developer in the dark room. 
 
BCA assay 
1. Add 0, 5, 10, 15, 20 µl of 1 mg/mL of BSA standard to corresponding wells in a 96-
well plate. 
2. Add 5 µl of protein sample (lysate) to 96-well plate. 
3. Add 200 µl of BCA mixture to each well containing sample.  (1 part solution B to 50 
parts solution A.) 
4.  Incubate plate for 30 minutes at 37 °C. 
5. Read plate at 562 nm using a microplate reader. 
 
 79
REFERENCES 
 
Adamson, P., Marshall, C.J., Hall, A., and Tilbrook, P.A. (1992). Post-translational 
modifications of p21rho proteins. J Biol Chem 267, 20033-20038. 
Ahn, S., Nelson, C.D., Garrison, T.R., Miller, W.E., and Lefkowitz, R.J. (2003). 
Desensitization, internalization, and signaling functions of beta-arrestins 
demonstrated by RNA interference. Proc Natl Acad Sci U S A 100, 1740-1744. 
Aktories, K., and Just, I. (2005). Clostridial Rho-inhibiting protein toxins. Curr Top 
Microbiol Immunol 291, 113-145. 
Aktories, K., Wilde, C., and Vogelsgesang, M. (2004). Rho-modifying C3-like ADP-
ribosyltransferases. Rev Physiol Biochem Pharmacol 152, 1-22. 
Benovic, J.L., Kuhn, H., Weyand, I., Codina, J., Caron, M.G., and Lefkowitz, R.J. 
(1987). Functional desensitization of the isolated beta-adrenergic receptor by the 
beta-adrenergic receptor kinase: potential role of an analog of the retinal protein 
arrestin (48-kDa protein). Proc Natl Acad Sci U S A 84, 8879-8882. 
Bishop, A.L., and Hall, A. (2000). Rho GTPases and their effector proteins. Biochem J 
348 Pt 2, 241-255. 
Bonifacino, J.S., and Traub, L.M. (2003). Signals for sorting of transmembrane proteins 
to endosomes and lysosomes. Annu Rev Biochem 72, 395-447. 
Braun, U., Habermann, B., Just, I., Aktories, K., and Vandekerckhove, J. (1989). 
Purification of the 22 kDa protein substrate of botulinum ADP-ribosyltransferase 
C3 from porcine brain cytosol and its characterization as a GTP-binding protein 
highly homologous to the rho gene product. FEBS Lett 243, 70-76. 
Cannizzaro, L.A., Madaule, P., Hecht, F., Axel, R., Croce, C.M., and Huebner, K. (1990). 
Chromosome localization of human ARH genes, a ras-related gene family. 
Genomics 6, 197-203. 
Cao, T.T., Deacon, H.W., Reczek, D., Bretscher, A., and von Zastrow, M. (1999). A 
kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-
adrenergic receptor. Nature 401, 286-290. 
Casey, P.J., and Seabra, M.C. (1996). Protein prenyltransferases. J Biol Chem 271, 5289-
5292. 
Chan, K.K., Oza, A.M., and Siu, L.L. (2003). The statins as anticancer agents. Clin 
Cancer Res 9, 10-19. 
 80
Chardin, P., Boquet, P., Madaule, P., Popoff, M.R., Rubin, E.J., and Gill, D.M. (1989). 
The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum 
exoenzyme C3 and affects actin microfilaments in Vero cells. Embo J 8, 1087-
1092. 
Collisson, E.A., Kleer, C., Wu, M., De, A., Gambhir, S.S., Merajver, S.D., and Kolodney, 
M.S. (2003). Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis 
in human melanoma cells. Mol Cancer Ther 2, 941-948. 
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., and Bernini, F. (1999). 
New insights into the pharmacodynamic and pharmacokinetic properties of 
statins. Pharmacol Ther 84, 413-428. 
Denoyelle, C., Vasse, M., Korner, M., Mishal, Z., Ganne, F., Vannier, J.P., Soria, J., and 
Soria, C. (2001). Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the 
signaling pathways involved in the invasiveness and metastatic properties of 
highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22, 
1139-1148. 
Fang, X., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., 
Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R.B., Wiener, J.R., Erickson, J.R., and 
Mills, G.B. (2000). Lysophospholipid growth factors in the initiation, progression, 
metastases, and management of ovarian cancer. Ann N Y Acad Sci 905, 188-208. 
Faried, A., Faried, L.S., Kimura, H., Nakajima, M., Sohda, M., Miyazaki, T., Kato, H., 
Usman, N., and Kuwano, H. (2006). RhoA and RhoC proteins promote both cell 
proliferation and cell invasion of human oesophageal squamous cell carcinoma 
cell lines in vitro and in vivo. Eur J Cancer 42, 1455-1465. 
Ferguson, S.S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the 
role in receptor desensitization and signaling. Pharmacol Rev 53, 1-24. 
Fernandez-Borja, M., Janssen, L., Verwoerd, D., Hordijk, P., and Neefjes, J. (2005). 
RhoB regulates endosome transport by promoting actin assembly on endosomal 
membranes through Dia1. J Cell Sci 118, 2661-2670. 
Furberg, C.D., and Pitt, B. (2001). Withdrawal of cerivastatin from the world market. 
Curr Control Trials Cardiovasc Med 2, 205-207. 
Gage, R.M., Matveeva, E.A., Whiteheart, S.W., and von Zastrow, M. (2005). Type I PDZ 
ligands are sufficient to promote rapid recycling of G Protein-coupled receptors 
independent of binding to N-ethylmaleimide-sensitive factor. J Biol Chem 280, 
3305-3313. 
Gampel, A., Parker, P.J., and Mellor, H. (1999). Regulation of epidermal growth factor 
receptor traffic by the small GTPase rhoB. Curr Biol 9, 955-958. 
 81
Ghosh, R.N., Mallet, W.G., Soe, T.T., McGraw, T.E., and Maxfield, F.R. (1998). An 
endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking 
through the endocytic recycling compartment in CHO cells. J Cell Biol 142, 923-
936. 
Goetzl, E.J., Lee, H., Dolezalova, H., Kalli, K.R., Conover, C.A., Hu, Y.L., Azuma, T., 
Stossel, T.P., Karliner, J.S., and Jaffe, R.B. (2000). Mechanisms of lysolipid 
phosphate effects on cellular survival and proliferation. Ann N Y Acad Sci 905, 
177-187. 
Grant, B., Zhang, Y., Paupard, M.C., Lin, S.X., Hall, D.H., and Hirsh, D. (2001). 
Evidence that RME-1, a conserved C. elegans EH-domain protein, functions in 
endocytic recycling. Nat Cell Biol 3, 573-579. 
Hajdo-Milasinovic, A., Ellenbroek, S.I., van Es, S., van der Vaart, B., and Collard, J.G. 
(2007). Rac1 and Rac3 have opposing functions in cell adhesion and 
differentiation of neuronal cells. J Cell Sci 120, 555-566. 
Hama, K., Aoki, J., Fukaya, M., Kishi, Y., Sakai, T., Suzuki, R., Ohta, H., Yamori, T., 
Watanabe, M., Chun, J., and Arai, H. (2004). Lysophosphatidic acid and autotaxin 
stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol 
Chem 279, 17634-17639. 
Hill, C.S., Wynne, J., and Treisman, R. (1995). The Rho family GTPases RhoA, Rac1, 
and CDC42Hs regulate transcriptional activation by SRF. Cell 81, 1159-1170. 
Horiuchi, A., Imai, T., Wang, C., Ohira, S., Feng, Y., Nikaido, T., and Konishi, I. (2003). 
Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor 
progression in ovarian carcinoma. Lab Invest 83, 861-870. 
Igel, M., Sudhop, T., and von Bergmann, K. (2002). Pharmacology of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin 
and pitavastatin. J Clin Pharmacol 42, 835-845. 
Ishii, I., Contos, J.J., Fukushima, N., and Chun, J. (2000). Functional comparisons of the 
lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and 
LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol 
Pharmacol 58, 895-902. 
Jalink, K., Hengeveld, T., Mulder, S., Postma, F.R., Simon, M.F., Chap, H., van der 
Marel, G.A., van Boom, J.H., van Blitterswijk, W.J., and Moolenaar, W.H. 
(1995). Lysophosphatidic acid-induced Ca2+ mobilization in human A431 cells: 
structure-activity analysis. Biochem J 307 ( Pt 2), 609-616. 
Kaibuchi, K., Kuroda, S., and Amano, M. (1999). Regulation of the cytoskeleton and cell 
adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 68, 
459-486. 
 82
Karnoub, A.E., Symons, M., Campbell, S.L., and Der, C.J. (2004). Molecular basis for 
Rho GTPase signaling specificity. Breast Cancer Res Treat 84, 61-71. 
Kikuchi, T., Nagata, Y., and Abe, T. (1997). In vitro and in vivo antiproliferative effects 
of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J 
Neurooncol 34, 233-239. 
Kim, Y.M., and Benovic, J.L. (2002). Differential roles of arrestin-2 interaction with 
clathrin and adaptor protein 2 in G protein-coupled receptor trafficking. J Biol 
Chem 277, 30760-30768. 
Kue, P.F., Taub, J.S., Harrington, L.B., Polakiewicz, R.D., Ullrich, A., and Daaka, Y. 
(2002). Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-
insensitive prostate cancer PC-3 cells. Int J Cancer 102, 572-579. 
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., and 
Nakamura, H. (2001). Inhibition of epidermal growth factor-induced RhoA 
translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-
methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61, 4885-4891. 
Lamaze, C., Chuang, T.H., Terlecky, L.J., Bokoch, G.M., and Schmid, S.L. (1996). 
Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 382, 177-
179. 
Lee, C.W., Rivera, R., Gardell, S., Dubin, A.E., and Chun, J. (2006). GPR92 as a new 
G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, 
LPA5. J Biol Chem 281, 23589-23597. 
Lefkowitz, R.J. (2000). The superfamily of heptahelical receptors. Nat Cell Biol 2, E133-
136. 
Lerner, E.C., Qian, Y., Blaskovich, M.A., Fossum, R.D., Vogt, A., Sun, J., Cox, A.D., 
Der, C.J., Hamilton, A.D., and Sebti, S.M. (1995). Ras CAAX peptidomimetic 
FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic 
accumulation of inactive Ras-Raf complexes. J Biol Chem 270, 26802-26806. 
Leung, K.F., Baron, R., and Seabra, M.C. (2006). Thematic review series: lipid 
posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 
47, 467-475. 
Lin, S.X., Grant, B., Hirsh, D., and Maxfield, F.R. (2001). Rme-1 regulates the 
distribution and function of the endocytic recycling compartment in mammalian 
cells. Nat Cell Biol 3, 567-572. 
Linder, S., and Aepfelbacher, M. (2003). Podosomes: adhesion hot-spots of invasive 
cells. Trends Cell Biol 13, 376-385. 
Madaule, P., and Axel, R. (1985). A novel ras-related gene family. Cell 41, 31-40. 
 83
Malecz, N., McCabe, P.C., Spaargaren, C., Qiu, R., Chuang, Y., and Symons, M. (2000). 
Synaptojanin 2, a novel Rac1 effector that regulates clathrin-mediated 
endocytosis. Curr Biol 10, 1383-1386. 
Mallard, F., Antony, C., Tenza, D., Salamero, J., Goud, B., and Johannes, L. (1998). 
Direct pathway from early/recycling endosomes to the Golgi apparatus revealed 
through the study of shiga toxin B-fragment transport. J Cell Biol 143, 973-990. 
Matar, P., Rozados, V.R., Binda, M.M., Roggero, E.A., Bonfil, R.D., and Scharovsky, 
O.G. (1999). Inhibitory effect of Lovastatin on spontaneous metastases derived 
from a rat lymphoma. Clin Exp Metastasis 17, 19-25. 
Maxfield, F.R., and McGraw, T.E. (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5, 
121-132. 
McGuire, T.F., Qian, Y., Vogt, A., Hamilton, A.D., and Sebti, S.M. (1996). Platelet-
derived growth factor receptor tyrosine phosphorylation requires protein 
geranylgeranylation but not farnesylation. J Biol Chem 271, 27402-27407. 
Mellor, H., Flynn, P., Nobes, C.D., Hall, A., and Parker, P.J. (1998). PRK1 is targeted to 
endosomes by the small GTPase, RhoB. J Biol Chem 273, 4811-4814. 
Meyer zu Heringdorf, D., and Jakobs, K.H. (2007). Lysophospholipid receptors: 
signalling, pharmacology and regulation by lysophospholipid metabolism. 
Biochim Biophys Acta 1768, 923-940. 
Mills, G.B., and Moolenaar, W.H. (2003). The emerging role of lysophosphatidic acid in 
cancer. Nat Rev Cancer 3, 582-591. 
Miquel, K., Pradines, A., Sun, J., Qian, Y., Hamilton, A.D., Sebti, S.M., and Favre, G. 
(1997). GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes 
G2-M enrichment in A549 cells. Cancer Res 57, 1846-1850. 
Muck, A.O., Seeger, H., and Wallwiener, D. (2004). Inhibitory effect of statins on the 
proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 42, 695-700. 
Mukai, M., Nakamura, H., Tatsuta, M., Iwasaki, T., Togawa, A., Imamura, F., and 
Akedo, H. (2000). Hepatoma cell migration through a mesothelial cell monolayer 
is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway. FEBS 
Lett 484, 69-73. 
Murph, M.M., Scaccia, L.A., Volpicelli, L.A., and Radhakrishna, H. (2003). Agonist-
induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via 
a Dynamin2- and Rab5-dependent pathway. J Cell Sci 116, 1969-1980. 
Murphy, C., Saffrich, R., Grummt, M., Gournier, H., Rybin, V., Rubino, M., Auvinen, P., 
Lutcke, A., Parton, R.G., and Zerial, M. (1996). Endosome dynamics regulated by 
a Rho protein. Nature 384, 427-432. 
 84
Murphy, C., Saffrich, R., Olivo-Marin, J.C., Giner, A., Ansorge, W., Fotsis, T., and 
Zerial, M. (2001). Dual function of rhoD in vesicular movement and cell motility. 
Eur J Cell Biol 80, 391-398. 
Naslavsky, N., Boehm, M., Backlund, P.S., Jr., and Caplan, S. (2004a). Rabenosyn-5 and 
EHD1 interact and sequentially regulate protein recycling to the plasma 
membrane. Mol Biol Cell 15, 2410-2422. 
Naslavsky, N., Weigert, R., and Donaldson, J.G. (2004b). Characterization of a 
nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol 
Cell 15, 3542-3552. 
Oakley, R.H., Laporte, S.A., Holt, J.A., Caron, M.G., and Barak, L.S. (2000). Differential 
affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-
coupled receptors delineate two major classes of receptors. J Biol Chem 275, 
17201-17210. 
Olofsson, B. (1999). Rho guanine dissociation inhibitors: pivotal molecules in cellular 
signalling. Cell Signal 11, 545-554. 
Paing, M.M., Stutts, A.B., Kohout, T.A., Lefkowitz, R.J., and Trejo, J. (2002). beta -
Arrestins regulate protease-activated receptor-1 desensitization but not 
internalization or Down-regulation. J Biol Chem 277, 1292-1300. 
Paterson, H.F., Self, A.J., Garrett, M.D., Just, I., Aktories, K., and Hall, A. (1990). 
Microinjection of recombinant p21rho induces rapid changes in cell morphology. 
J Cell Biol 111, 1001-1007. 
Pereira-Leal, J.B., Hume, A.N., and Seabra, M.C. (2001). Prenylation of Rab GTPases: 
molecular mechanisms and involvement in genetic disease. FEBS Lett 498, 197-
200. 
Pille, J.Y., Denoyelle, C., Varet, J., Bertrand, J.R., Soria, J., Opolon, P., Lu, H., Pritchard, 
L.L., Vannier, J.P., Malvy, C., Soria, C., and Li, H. (2005). Anti-RhoA and anti-
RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast 
cancer cells in vitro and in vivo. Mol Ther 11, 267-274. 
Pitcher, J.A., Freedman, N.J., and Lefkowitz, R.J. (1998). G protein-coupled receptor 
kinases. Annu Rev Biochem 67, 653-692. 
Presley, J.F., Mayor, S., Dunn, K.W., Johnson, L.S., McGraw, T.E., and Maxfield, F.R. 
(1993). The End2 mutation in CHO cells slows the exit of transferrin receptors 
from the recycling compartment but bulk membrane recycling is unaffected. J 
Cell Biol 122, 1231-1241. 
Qualmann, B., and Kessels, M.M. (2002). Endocytosis and the cytoskeleton. Int Rev 
Cytol 220, 93-144. 
 85
Radeff-Huang, J., Seasholtz, T.M., Matteo, R.G., and Brown, J.H. (2004). G protein 
mediated signaling pathways in lysophospholipid induced cell proliferation and 
survival. J Cell Biochem 92, 949-966. 
Ridley, A. (2000). Rho GTPases. Integrating integrin signaling. J Cell Biol 150, F107-
109. 
Ridley, A.J. (2001). Rho family proteins: coordinating cell responses. Trends Cell Biol 
11, 471-477. 
Ridley, A.J. (2004). Rho proteins and cancer. Breast Cancer Res Treat 84, 13-19. 
Ridley, A.J., and Hall, A. (1992). The small GTP-binding protein rho regulates the 
assembly of focal adhesions and actin stress fibers in response to growth factors. 
Cell 70, 389-399. 
Ridley, A.J., Schwartz, M.A., Burridge, K., Firtel, R.A., Ginsberg, M.H., Borisy, G., 
Parsons, J.T., and Horwitz, A.R. (2003). Cell migration: integrating signals from 
front to back. Science 302, 1704-1709. 
Riento, K., and Ridley, A.J. (2003). Rocks: multifunctional kinases in cell behaviour. Nat 
Rev Mol Cell Biol 4, 446-456. 
Ruth, M.C., Xu, Y., Maxwell, I.H., Ahn, N.G., Norris, D.A., and Shellman, Y.G. (2006). 
RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J 
Invest Dermatol 126, 862-868. 
Sahai, E., and Marshall, C.J. (2002). ROCK and Dia have opposing effects on adherens 
junctions downstream of Rho. Nat Cell Biol 4, 408-415. 
Schmid, S.L. (1997). Clathrin-coated vesicle formation and protein sorting: an integrated 
process. Annu Rev Biochem 66, 511-548. 
Schmidt, A., and Hall, A. (2002). Guanine nucleotide exchange factors for Rho GTPases: 
turning on the switch. Genes Dev 16, 1587-1609. 
Shao, F., and Dixon, J.E. (2003). YopT is a cysteine protease cleaving Rho family 
GTPases. Adv Exp Med Biol 529, 79-84. 
Sheff, D.R., Daro, E.A., Hull, M., and Mellman, I. (1999). The receptor recycling 
pathway contains two distinct populations of early endosomes with different 
sorting functions. J Cell Biol 145, 123-139. 
Shenoy, S.K., and Lefkowitz, R.J. (2003). Multifaceted roles of beta-arrestins in the 
regulation of seven-membrane-spanning receptor trafficking and signalling. 
Biochem J 375, 503-515. 
 86
Shenoy, S.K., McDonald, P.H., Kohout, T.A., and Lefkowitz, R.J. (2001). Regulation of 
receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-
arrestin. Science 294, 1307-1313. 
Song, J., Khachikian, Z., Radhakrishna, H., and Donaldson, J.G. (1998). Localization of 
endogenous ARF6 to sites of cortical actin rearrangement and involvement of 
ARF6 in cell spreading. J Cell Sci 111 ( Pt 15), 2257-2267. 
Stam, J.C., Michiels, F., van der Kammen, R.A., Moolenaar, W.H., and Collard, J.G. 
(1998). Invasion of T-lymphoma cells: cooperation between Rho family GTPases 
and lysophospholipid receptor signaling. Embo J 17, 4066-4074. 
Stark, W.W., Jr., Blaskovich, M.A., Johnson, B.A., Qian, Y., Vasudevan, A., Pitt, B., 
Hamilton, A.D., Sebti, S.M., and Davies, P. (1998). Inhibiting 
geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular 
smooth muscle cells. Am J Physiol 275, L55-63. 
Su, Y., Raghuwanshi, S.K., Yu, Y., Nanney, L.B., Richardson, R.M., and Richmond, A. 
(2005). Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. J 
Immunol 175, 5396-5402. 
Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. (1998). Both farnesyltransferase and 
geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-
Ras prenylation but each alone is sufficient to suppress human tumor growth in 
nude mouse xenografts. Oncogene 16, 1467-1473. 
Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., 
Hiai, H., and Fukumoto, M. (1998). Overexpression of the rhoC gene correlates 
with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77, 147-
152. 
Symons, M., and Rusk, N. (2003). Control of vesicular trafficking by Rho GTPases. Curr 
Biol 13, R409-418. 
Teo, M., Tan, L., Lim, L., and Manser, E. (2001). The tyrosine kinase ACK1 associates 
with clathrin-coated vesicles through a binding motif shared by arrestin and other 
adaptors. J Biol Chem 276, 18392-18398. 
Toews, M.L., Ustinova, E.E., and Schultz, H.D. (1997). Lysophosphatidic acid enhances 
contractility of isolated airway smooth muscle. J Appl Physiol 83, 1216-1222. 
Ullrich, O., Reinsch, S., Urbe, S., Zerial, M., and Parton, R.G. (1996). Rab11 regulates 
recycling through the pericentriolar recycling endosome. J Cell Biol 135, 913-
924. 
Urs, N.M., Jones, K.T., Salo, P.D., Severin, J.E., Trejo, J., and Radhakrishna, H. (2005). 
A requirement for membrane cholesterol in the beta-arrestin- and clathrin-
 87
dependent endocytosis of LPA1 lysophosphatidic acid receptors. J Cell Sci 118, 
5291-5304. 
van Corven, E.J., van Rijswijk, A., Jalink, K., van der Bend, R.L., van Blitterswijk, W.J., 
and Moolenaar, W.H. (1992). Mitogenic action of lysophosphatidic acid and 
phosphatidic acid on fibroblasts. Dependence on acyl-chain length and inhibition 
by suramin. Biochem J 281 ( Pt 1), 163-169. 
van der Sluijs, P., Hull, M., Webster, P., Male, P., Goud, B., and Mellman, I. (1992). The 
small GTP-binding protein rab4 controls an early sorting event on the endocytic 
pathway. Cell 70, 729-740. 
van Leeuwen, F.N., Giepmans, B.N., van Meeteren, L.A., and Moolenaar, W.H. (2003). 
Lysophosphatidic acid: mitogen and motility factor. Biochem Soc Trans 31, 1209-
1212. 
Veillard, N.R., and Mach, F. (2002). Statins: the new aspirin? Cell Mol Life Sci 59, 
1771-1786. 
Vogt, A., Qian, Y., McGuire, T.F., Hamilton, A.D., and Sebti, S.M. (1996). Protein 
geranylgeranylation, not farnesylation, is required for the G1 to S phase transition 
in mouse fibroblasts. Oncogene 13, 1991-1999. 
Vogt, A., Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. (1997). The 
geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in 
G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol 
Chem 272, 27224-27229. 
Wallar, B.J., and Alberts, A.S. (2003). The formins: active scaffolds that remodel the 
cytoskeleton. Trends Cell Biol 13, 435-446. 
Wang, D.A., Lorincz, Z., Bautista, D.L., Liliom, K., Tigyi, G., and Parrill, A.L. (2001). A 
single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) 
and LPA1 (EDG2) phospholipid growth factor receptors. J Biol Chem 276, 
49213-49220. 
Wolfe, B.L., and Trejo, J. (2007). Clathrin-dependent mechanisms of G protein-coupled 
receptor endocytosis. Traffic 8, 462-470. 
Wu, M., Wu, Z.F., Kumar-Sinha, C., Chinnaiyan, A., and Merajver, S.D. (2004). RhoC 
induces differential expression of genes involved in invasion and metastasis in 
MCF10A breast cells. Breast Cancer Res Treat 84, 3-12. 
Xiao, K., Garner, J., Buckley, K.M., Vincent, P.A., Chiasson, C.M., Dejana, E., Faundez, 
V., and Kowalczyk, A.P. (2005). p120-Catenin regulates clathrin-dependent 
endocytosis of VE-cadherin. Mol Biol Cell 16, 5141-5151. 
 88
Xu, Y., Fang, X.J., Casey, G., and Mills, G.B. (1995). Lysophospholipids activate 
ovarian and breast cancer cells. Biochem J 309 ( Pt 3), 933-940. 
Zalcman, G., Closson, V., Linares-Cruz, G., Lerebours, F., Honore, N., Tavitian, A., and 
Olofsson, B. (1995). Regulation of Ras-related RhoB protein expression during 
the cell cycle. Oncogene 10, 1935-1945. 
Zhang, J., Barak, L.S., Anborgh, P.H., Laporte, S.A., Caron, M.G., and Ferguson, S.S. 
(1999). Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic 
complexes. J Biol Chem 274, 10999-11006. 
Zhang, J., Ferguson, S.S., Barak, L.S., Aber, M.J., Giros, B., Lefkowitz, R.J., and Caron, 
M.G. (1997). Molecular mechanisms of G protein-coupled receptor signaling: role 
of G protein-coupled receptor kinases and arrestins in receptor desensitization and 
resensitization. Receptors Channels 5, 193-199. 
Zong, H., Raman, N., Mickelson-Young, L.A., Atkinson, S.J., and Quilliam, L.A. (1999). 
Loop 6 of RhoA confers specificity for effector binding, stress fiber formation, 
and cellular transformation. J Biol Chem 274, 4551-4560. 
 
 
